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INTRODUCTION: 
THE COMPLEMENT SYSTEM IN HISTORICAL PERSPECTIVE 
 
 
Abbreviations  
AP   : alternative complement pathway  
C1-INH : C1 esterase inhibitor 
CP  : classical complement pathway  
CR1  : complement receptor 1 (CD35) 
CRP  : C-reactive protein 
DAF  : decay-accelerating factor (CD55) 
Ig  : immunoglobulin 
LP  : lectin complement pathway  
MBL  : mannose-binding lectin 
MCP  : membrane cofactor protein (CD46) 
MHC  : major histocompatibility complex 
RCA  : regulators of complement activation 
SLE  : systemic lupus erythomatosus 
 
Classification of species or phyla in evolution  
Agnatha : jawless vertebrates like hagfish and lamprey 
Ascidian: : belongs to the subphylum urochordata 
Chordata: : phylum comprising urochordata, cephalochordata and vertebrata 
Cyclostome  : e.g. lamprey 
Deuterostome    : comprises two major phyla, the chordata (including mammals) and the  
  echinodermata  
Echinodermata   : (ekhinos = sea urchin, derma = skin) phylum including sea urchins, sea stars, and  
  seacucumbers 
Invertebrates  : echinoderms, and protochordates like Clavelina picta and the ascidian  
                               Halocynthia roretzi 
Teleost fish : bony fish like trout, sand bass, and puffer fish 
Tunicate : belongs to the phylum of the urochordata 
Urochordata : subphylum  
Vertebrates : classified in jawless (Agnatha) or jawed species 
 
 
THE COMPLEMENT SYSTEM  
 
1.1 Overview of the complement system  (Fig. 1) 
 
    The immune system in human and other mammals is composed of two major subsystems 
(Table 1): the innate immune system and the adaptive immune system. The adaptive 
immune system, which is organized around B- and T lymphocytes, is very flexible in its 
adaptation to molecular changes in varying pathogens. However, reactions to unknown 
foreign contacts are slow, since it takes three to seven days before clonal selection and 
expansion of lymphocytes ensures a specific immune response. On the other hand, the 
innate immune system, which can be defined as all immune defenses that lack 
immunological memory, is quick to respond (in minutes to hours), and has evolved from 
ongoing associations between host and pathogen [1,2,3,4]. Nowadays, the innate 
immune response is understood to be essential to the function of the adaptive immune 
response [5].  
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Figure 1. An overview of the complement system: the three complement activation pathways of the 
complement system and the effector pathway (terminal pathway). 
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Table 1. A simplified version of human immunity [1,2]. 
 
Innate immunity 
 
 
 
 
 
 
 
 
Cellular 
 
 
Humoral 
(soluble) 
 
 
 
Phagocytes: monocytes, macrophages, neutrophils 
Dendritic cells 
Natural killer cells 
Complement: 
   `  MBL or lectin complement activation pathway (LP) 
   `  Alternative complement activation pathway (AP) 
   `  Classical complement activation pathway (CP) 
Acute phase proteins 
Cytokines e.g. interferon 
Chemokines 
Adaptive immunity Cellular 
Humoral 
T lymphocytes, B lymphocytes 
Antibodies (secreted by B lymphocytes or memory cells) 
 
 
 
    The complement system, focus of this thesis, is an important system in innate immunity 
and consists of over thirty different proteins. Synthesis of complement proteins occurs 
mainly in the liver, and in monocytes and macrophages, phagocytic cells that are part of 
innate immunity. Activation of the complement system results in a triggered enzyme 
cascade, analogous to cascades in coagulation, fibrinolysis, and the kinin pathway [1]. 
    The complement system is involved in the innate recognition and elimination of 
antigen-antibody complexes and foreign microbes or molecules from the body. 
Clearance is mostly mediated by the mononuclear phagocytic system, consisting of 
monocytes and macrophages in liver, spleen, lymph nodes, or in the inflamed tissue itself, 
e.g. the lungs. In primates, erythrocytes have the function of transporting immune 
complexes to the liver or spleen for immune clearance [6,7]. Since human erythrocytes 
carry complement receptor 1 (CR1) molecules on their surface, immune complexes 
adhere to the CR1 molecules with the aid of C4b and C3b, by a process called ‘immune 
adherence’ or ‘the red cell adhesion phenomenon’ [8,9,10]. In mice, platelets carry CR1 
receptors, which makes these cells mediators of immune adherence [11].  
    Although complement was first described by the end of the 19th century, it was only in 
the 1960s that separation techniques became available which allowed the purification 
and the functional characterization of the components involved in the antibody-
dependent classical pathway, and the antibody-independent alternative pathway. The 
antibody-independent lectin pathway was recognized only a decade ago. 
 
 
1.2 Complement activation pathways and C3 conversion 
 
    The key position in the complement system is held by C3. This complement 
component is the most abundant, being present in normal plasma at levels up to 1.3 
mg/ml [12]. The activation of C3 into C3b and C3a is mediated by so-called C3-
convertases, which are the products of the three different complement activation 
pathways. In turn, C3b exposes a highly reactive thioester group that then reacts with 
foreign materials, e.g. immune complexes or carbohydrates. 
    The complement activation pathways include, in order of descending evolutionary 
age, the lectin pathway (LP), the ‘alternative’ pathway (AP) and a third pathway, 
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inappropriately named the ‘classical’ pathway (CP), though this pathway is 
phylogenetically the youngest. These activation pathways either lead to coating of 
microbes, immune complexes, and/or cells with C3b (opsonization) or to the initiation of 
‘terminal pathway’ activation, which involves a series of events resulting in cellular 
membrane destabilization by pore formation. Thus, killing of e.g. Gram-negative bacteria 
and virus-infected cells is achieved. 
 
 
1.2.1 The lectin pathway of complement activation 
 
    The lectin pathway (LP) was only discovered in 1989 [13]. Activation of the lectin 
pathway starts with the recognition and binding of foreign bodies by a serum lectin called 
mannose-binding lectin (MBL). MBL is a high-molecular-weight protein, present in blood 
plasma in minute amounts (about 1.7 µg per ml). See Figure 2. MBL belongs to the family 
of collagenous lectins (collectins), together with human CL-L1 [14], CL-P1 [15], lung 
surfactant proteins A and D, and the bovine proteins conglutinin [16], collectin-43 [17], 
and collectin-46 [18].  
 
Figure 2. A side view of the tetrameric form of human 
mannose-binding lectin (MBL), based on four identical 
subunits. Each MBL head contains three C-type lectin 
domains that are carbohydrate recognition sites 
(CRD). MASPs interact with the collagenous regions. 
The four exons of the human MBL gene encode for the 
protein regions shown. MASP: MBL-associated serine 
protease [25]. 
 
 
 
    Upon binding to foreign bodies, MBL undergoes a conformational change leading to 
the coordinate activation of at least two MBL-associated proteins (MASP-1, and MASP-
2) and the generation of the active form of MASP-2, the LP-dependent C4/C2 
convertase [19]. MASP-1 is capable of direct C3 and C2 cleavage [20,21], but 
MAp19 lacks proteinase activity and its function is unknown [22,23]. The role of a 
recently discovered fourth MBL-associated serine proteinase, MASP-3, an alternative 
splicing product of the MASP1/3 gene, probably involves downregulation MASP-2 
activity as shown by in-vitro experiments [24]. C4/C2 convertase essentially generates 
three products from its substrates C2 and C4. These are C4bC2a and the split products 
C4a and C2b. Substrate-bound C4bC2a is a C3 convertase, allowing the conversion of 
C3 into C3a and C3b, which is the key reaction leading to terminal complement 
pathway initiation.  
    MBL mediates the recognition of foreign particles by its three identical sugar-binding 
domains with specificity for mannose, N-acetylglucosamine, and fucose [25]. The cell 
wall of fungi is relatively rich in mannan (polymerized mannose), while peptidoglycan of 
Gram-positive bacteria contains large amounts of N-acetylglucosamine, making these 
microorganisms ideal substrates for the lectin pathway [26,27]. IgA, a heavily 
mannosylated immunoglobulin and important mediator in mucosal immunity, activates 
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the lectin pathway, and is thought to act synergistically with MBL in defense [28]. One 
can also speculate on the MBL-activating properties of IgD. A cellular receptor for MBL 
has only been recognized recently, i.e. CR1 (complement receptor 1, CD35, C3b/C4b 
receptor) that is present on the surface of erythrocytes and inflammatory cells [29]. 
 
Table 3. Initiators of the three complement activation pathways. 
complement activation pathways initiators of complement activation pathways 
lectin complement pathway 
 
 
alternative complement pathway 
classical complement pathway 
microbes with exposed mannose, fucose, GlcNAc* 
lipoproteins** 
apoptotic cells # 
bacteria, viruses, fungi, tumor cells 
certain viruses and Gram-negative bacteria 
immune complexes 
apoptotic cells 
ligand-bound CRP ## 
*GlcNAc: N-acetyl-D-glucosamine. ** This thesis, chapter 7. # Ogden et al [30] and Raaschou-Jensen 
[31]. ## CRP: C-reactive protein. 
 
 
1.2.2 The alternative pathway (AP) of complement activation 
 
    The alternative pathway was first described in 1956 by Pillemer et al. [32]. However, 
it took more than 15 years until the pathway became generally accepted by 
complementologists [33]. Nowadays, we know that the main function of the antibody-
independent alternative pathway is to increase the number of C3b and inactivated C3b 
(C3bi) molecules on the substrates of complement activation. Thereby, the recognition 
and clearance of foreign bodies and immune complexes is accomplished. C3b deposition 
on the activating surface leads to an explosive instigation of the ‘amplification loop’, 
which is kept in check by the cell-bound complement inhibitors DAF (CD55) and MCP 
(CD46), and the soluble serum factors H and I. Activating surfaces include bacteria (LPS, 
teichoic acid), fungi, parasites, viruses, virally infected cells, and tumor cells like 
lymphoblastoid cells [12]. 
    Once formed, C3-convertase(s) will be amplified by amplification loop. This may be 
achieved in the following way: a C3 convertase will activate C3 into C3a and C3b, the 
very last of which will be covalently bound to the surface of activation (e.g. a 
microorganism). Next, C3b will bind AP component factor B which, in turn, will be 
activated by AP component factor D, also termed ‘adipsin’ [12]. The AP-dependent C3-
convertase C3bBb is then formed, as well as split product Ba, which is a leukotaxin. 
Properdin, the first identified AP component, stabilizes C3bBb, thereby greatly 
increasing its half-life, and promoting the generation of AP-dependent C5 convertases 
(C3bBbC3b). Down-regulation of the amplification loop is effectuated through factor I, 
which uses soluble factor H as a cofactor or cell-surface proteins MCP and CR1.  
 
 
1.2.3 The classical pathway of complement activation 
 
    Phylogenetically considered the youngest complement activation route, the classical 
pathway (CP) depends on IgG and/or IgM antibodies that are present in higher life forms 
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(mammals), but also cartilagenous and bony fish. The CP is very similar to the lectin 
pathway and may even have been derived from it, since CP component C1, consisting of 
C1q, C1r and C1s, is phenotypically and functionally related to the MBL/MASP-
1/MASP-2 complex [34]. Moreover, the LP and CP share components C4 and C2. 
Experimental evidence showed that the first CP component C1q can bind Gram-
negative bacteria with exposed lipid A, and exists in association with proenzymic C1r2s2. 
The C3b receptor (CR1), present on erythrocytes and leukocytes, can act as a receptor 
for both C1q [35] and MBL [29], which again stresses the functional relationship 
between C1 and MBL. 
 
 
Table 3. Physiologic activities ascribed to components of the human complement system, adapted from 
[1]. 
ACTIVITY       COMPLEMENT PROTEINS INVOLVED 
Host defense 
opsonization       covalently bound C3 and C4 fragments  
chemotaxis and leukocyte activation            C4a, C3a, C5a (anaphylatoxins); anaphylatoxin 
   receptors on leukocytes 
lysis of bacteria, cells, particles     MAC (C5b-9) 
 
Clearance of particles 
immune complexes      C1q; covalently bound C3 and C4 fragments  
apoptotic cells       C1q; covalently bound C3 and C4 fragments; MBL# 
lipoproteins *       MBL; covalently bound C3 and C4 fragments  
ds-DNA, ss-DNA **      MBL ? ** 
 
Interface innate and adaptive immunity   
augmentation of antibody repsonses            C3b and C4b bound to IC and Ag; C3 receptors on B 
                                                                            cells and APCs  
 
enhancement of immunological memory     C3b and C4b bound to IC and Ag; C3 receptors on 
                                                                             follicular dendritic cells 
 
# Ogden et al, 2001; Raaschou-Jensen, 2001. * This thesis, chapter 7. ** This thesis, chapter 7. IC: 
immune complexes. Ag : antigen. APC: antigen-presenting cell. 
 
 
1.2.4 The terminal complement pathway  
 
    Starting point of the terminal complement pathway is the formation of C5 convertases 
(C4bC2aC3b and/or C3bBbC3b) which mediate the conversion of C5 into C5b and 
C5a, a potent chemoattractant. The former complexes with C6 and C7, the resultant of 
which is a soluble complex with affinity for membranous bilayers. Upon insertion into e.g. 
Gram-negative bacteria, C8 will bind to the complex, thereby forming a new membrane-
bound enzyme (C5b-8) with membrane-bound C9 polymerase activity. Under the 
influence of C5b-8, some 13 C9 molecules become polymerized, resulting in a 
functional cylindric pore through the membrane. Depending on the presence of bacterial 
capsules and/or the total number of C9 molecules, target cells either resist membrane 
attack or are lysed through osmotic imbalance.  
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1.3 Regulators and modulators of the complement system 
 
    Unwanted activation of the complement cascade is prevented by both cell-bound and 
fluid-phase regulators and modulators. Soluble complement inhibitors include the 
following proteins:   
 
C1 esterase inhibitor (C1-INH): an inhibitor of the classical complement pathway 
through equimolar binding to C1r and C1s, leading to the dissociation of the C1 
complex [12]. In a similar way, C1-INH binds to MASP-2 and inhibits MASP-2-
associated C4-cleaving activity, thereby inhibiting the lectin complement pathway too 
[36]. The protein is present in human serum at 0.15 to 0.35 mg/ml. It belongs to the 
serpin (serine proteinase inhibitor) superfamily that is present in plants, invertebrates and 
vertebrates, functioning in complement, coagulation, fibrinolysis, contact activation, and 
transport [12]. 
 
C3b inactivator (factor I): acts in conjunction with factor H in the conversion of C3b into 
C3bi. This intermediate can still act as an opsonin, but not as an active enzyme in the AP 
[12]. 
 
α2-Macroglobulin (α2M): belongs to the C3/C4/C5 thioester protein family and 
functions as a natural regulator of proteinases. Also, α2M may prevent LP activation 
through direct binding, or it can interfere with MASP-induced C4 cleavage  [37,38]. 
However, this finding has not been confirmed by others, including ourselves [39-41]. 
 
Factor H and factor H-like molecules: act at the level of factor B binding to target-bound 
C3b, thereby preventing the formation of AP-dependent C3 convertases. Binding of 
factor H also regulates the LP through binding of C3b [42]. C-reactive protein (CRP) 
may inhibit factor H by binding which, in turn, controls the LP, but the significance of this 
finding is not clear [43]. Factor H belongs to the family of regulators of C3 and C4 
activation and degradation, a family of proteins displaying repeating elements called 
complement control proteins (CCP’s), and whose genes are located in a cluster on 
chromosome 1. 
 
    Cell-bound complement regulators include complement receptor 1 (CR1), which has a 
factor-H-like co-enzyme function versus factor I, DAF and MCP, together called the 
three membrane-bound regulators of complement activation (RCA) proteins [44]. In 
man, CR1 is a transmembrane glycoprotein present on all types of blood cells except 
thrombocytes. In the circulation, 90 to 95 % of CR1 is expressed by erythrocytes, on the 
surface of which CR1 acts as a carrier protein [6,9,10] for bound immune complexes 
towards liver and spleen for transfer to macrophages [45]. The ligands for CR1 are C1q 
[35,46], MBL [29], C4b, C3b, and C3bi [12]. CR1 deactivates convertases by decay 
acceleration, and has cofactor activity for factor I-mediated cleavage of C3b and C4b. 
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1.4 The evolution of the complement system 
 
1.4.1 Findings in nature 
 
    Phylogenetic studies have shown that the terminal and the classical pathways are 
relatively young (350-400 million years) when compared with the alternative and lectin 
pathways (over 700 million years old; Fig.3) [47]. The evolutionary studies have 
revealed that the three complement activation pathways and the terminal pathway are 
present in cartilaginous fishes (e.g. sharks) and higher vertebrates, while the classical and 
terminal pathways are lacking in the most primitive existent vertebrates like the lamprey 
(a jawless fish; Agnatha)[47-49]. 
    The adaptive immune response, which must have appeared about 450 million years 
ago [50], is found in cartilaginous fish (sharks), in bony fish like salmon, and in the higher 
life forms, but is inefficient or absent in jawless fish and invertebrates [51]. In contrast, the 
complement system of cold-blooded vertebrates shows more diversity and greater 
activity than in higher life forms [47]. For example, the alternative pathway in fish is up to 
ten times as active as compared to higher vertebrates, which may offer a kind of 
compensation for the lack of adaptive immunity [50,52]. The AP component factor D 
has been found only in bony fish and higher evolved organisms. The only known member 
of the RCA (regulators of complement activation) family found in lower vertebrates, like 
teleost fish, are factor H and sand bass proteins SBp1 and SBCRP-1 [53].  The terminal 
complement components C5b, C6, C7, C8a, C8b, and C9 homologues are present in 
bony fish and higher life forms, but the most ancient fish lack a functional terminal 
pathway. 
      Which complement homologues have been identified in the lower part of the 
evolutionary tree? Evolutionary homologues of the key protein C3 have been identified 
in sea urchins and tunicates, lower phyla sharing characteristics with vertebrates [54]. In 
the invertebrate tunicate Styela plicata, a calcium-dependent lectin has been isolated. 
Also, two other complement components, MASP and factor B, have been identified in 
invertebrates like deuterostomes, e.g. sea urchins and sea stars [55], confirming a simple 
complement system with less components and fewer pathways in the lower phyla. In 
ascidians, no C2 or C4 is found, but C3 molecules with opsonic activity are present, as 
are MASP homologues, although no functional study has been done to demonstrate C3-
cleaving activity of these homologues, yet.  
    Until recently, the alternative pathway was considered to be more primitive and hence 
older than the lectin pathway in evolutionary terms.  However, certain important findings 
question this view [48,49,56]. For example, factor D has been found only in bony and 
cartilagenous fish and in higher species, but not in the jawless fish (Agnatha) and other 
lower life forms. Even more convincing is the evidence that lectins and MASPs are 
present not only in vertebrates but also in invertebrates. In deuterostomes, e.g. sea 
urchins and sea stars, C3 homologues, MASP and factor B chave been identified 
[55,57]. Moreover, in the ascidian Halocynthia roretzi, beside C3, two MASPs have 
been found, with close similarity to MASP-1 [58]. In the evolutionary tree, ascidians 
belong to the urochordata with a phylogenetical position between vertebrates and true 
invertebrates. Finally, MBL-like proteins have been found in invertebrates like the 
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protochordate Clavelina picta [59], the tunicate Styela plicata [54], and in insects like 
the cockroach Blaberus discoidalis [60].   
    In conclusion, these finding provide evidence that the lectin-dependent complement 
pathway was present prior to the emergence of vertebrates in evolution [51,58].  
 
 
1.4.2. Protein families  
 
    The evolution of the complement system coincided with the appearance of the 
adaptive immune system. This was concluded from the discovery of recombinase 
activating genes (RAG) in jawed vertebrates, resulting in the ability to carry out gene 
arrangements and to generate duplicated genes available for altered function [55]. The 
finding of similarities in protein sequence and function, as well as the close organization 
of some complement genes, have led to the theory that, in higher vertebrates, the 
complement cascade evolved from a few primordial genes through gene duplication 
[61].  
    Similarities in protein sequence and function are found in the α2M/C4/C3/C5-
thioester protein family. The only thioester protein found in invertebrates like the 
horseshoe crab Limulus polyphemus is α2-macroglobulin [62], lending support to the idea 
that α2-macroglobulin predates the other members of the family. However, the genes 
expressing the different thioester proteins are not found on one particular chromosome, 
but on different chromosomes.  
    A second protein family is formed by the RCA family. Found in bony fish, this protein 
family consists of CR1, CR1-like proteins, CR2, factor H, factor H-like proteins, DAF, 
and MCP. Later in evolution, however, the RCA family probably evolved into two 
different groups based on varying homology of protein sequences [53]. Sponges already 
contained molecules with CCP repeats that are highly homologous to the RCA family 
[63], providing evidence for the existence of precursors earlier in evolution. However, 
the evolution of this family of molecules remains to be elucidated. 
    The serine proteinases involved in the complement system consist of C1r, C1s, C2, 
factor B, factor D, factor I and the MASPs. As a third example of protein families, the 
constituents of the C1r/C1s/MASP-1/MASP-2 family are found to be phenotypically 
and functionally related [41]. MASP-1 is more similar to C1r than to C1s. Based on 
amino-acid sequence, two groups of serine proteases can be identified in the 
complement system [64]. The first group is the AGY-type (encoding an active serine site 
encoded by AGY), found solely in vertebrates, and which includes C1r, C1s, and MASP-
2, each protein being encoded by a single exon. The second group is called the TCN-
type, encoding a histidine loop also found in digestive enzymes and coagulation factors. 
The TCN-type group comprises MASP-1, factors B, D, and I, and C2 [65]. These finding 
suggest that the TCN-type is the evolutionary prototype of the MASP/C1r/C1s family. 
Probably, the classical pathway, being very similar to the lectin pathway, has evolved 
from the more ancient MBL/MASPs pathway at the evolutionary stage between 
cyclostomes and cartilaginous fish [65]. 
    Ancient complement components of the major histocompatibility complex (MHC) 
class III molecules are C4A, C4B, C2, and factor B, but the question if the MHC is, or 
has been, present in life-forms lower than jawed fish remains unanswered. Gene 
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duplications that gave rise to C4/C3/C5 and factor B/C2 occurred only in vertebrates, 
but not in the invertebrate lineage. Again, this provides evidence for the theory that the 
lectin pathway is older than the alternative pathway [56,58]. 
 
 
1.5 The ancient complement system  
  
    The afore-mentioned information suggests that in ancient times (before the jawed fish 
evolved) some kind of primordial complement system must have existed, consisting of the 
following components (Fig. 3):     
 
1. C3, the presence of with indicates at least a primitive complement system; ascidian 
C3 is opsonic, i.e. it enhances the phagocytosis of particles by coelomocytes or ascidian 
blood cells, 
 
2. the lectin-MASP pathway, as the first self and non-self discriminatory system leading 
to deposition of C3b on target particles, 
 
3. the alternative pathway, functioning as a C3b-amplification system; this pathway 
harbors factor B (Bf); Bf derived from sea urchins and ascidians possess additional short 
consensus repeat (SCR) domains and low-density lipoprotein receptor (LDLr) domains of 
which the function is unknown [58]. 
 
4. a possible equivalent of the ‘immune adherence’ phenomenon, which, in primates, 
involves the C3b-receptor (CR1 = CD35) on erythrocytes, similar to the thrombocyte 
compartment in rodents. Human erythrocytes carry between 500 and 1200 CR1 
molecules on their surface [12,66], which are able to bind C3b-coated particles. These 
particles are then transported from their site of formation or production to target organs 
like the spleen, the liver, or any ‘macrophage-rich’ predator organ that may take care of 
the elimination of foreign particles in earlier life forms. The presence of CR1 in the lower 
phyla is unknown, and the evolution of CR1 is still unsolved (personal communication, 
2002, Dr. F. Beurskens, Dr. Lloyd Klickstein, Brigham Women’s Hospital, Boston, USA). 
However, CR3 and CR4 have been identified in lower phyla. Targets of C3b binding in 
lower phyla may consist of thrombocytes or more primitive hemocytes. 
 
 
1.6 Can complement deficiencies clarify complement function?   
 
    Complete C4 deficiency is extremely rare but invariably leads to autoimmunity (SLE, 
and renal immune complex disease), and increased susceptibility to bacterial infections. 
Partial C4A or C4B deficiencies in the Caucasian population have a combined 
frequency of 31.6%. However, deficiency of C4B, which is more hemolytically active, 
has only incidentally been described to be associated with Gram-negative infections , 
while the body of literature on partial C4A deficiency points towards an increased risk of 
developing immune complex disease like SLE. Target-bound C4b of the A isotype is a 
better ligand for CR1 than C4b of the B isotype [67]. 
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Figure 3. Evolution of the complement system as published by Sunyer et al [47]. Reproduced with 
permission from the publisher. 
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Figure 4. Proposed pathway for opsonization and immune adherence (IA). 
 
 
            C4A pathway    → C3 → C3a + C3b (particle opsonization, IA, transport) 
   MBL /MASP 
       C1qr2s2           C4B pathway    →  C5  → C5b - C9   (cytolysis, ‘killing’) 
 
 
 
    Over 12% of the Dutch population has low MBL serum levels (< 0.42 mg/L), as is 
shown is chapter 3, which is in line with MBL deficiency figures in other Caucasian 
populations. The prevalence of MBL deficiency in sub-Saharan Africa is much higher, 
over 30%, with a high C allele frequency of 0.24 [68]. One could speculate that MBL 
deficiency has or has had a relative evolutionary advantage, e.g. because it makes the 
MBL-deficient subject more resistant towards certain lethal infectious disease with e.g. 
mycobacteria and leishmania parasites [69-71]. In the northern European population, 
MBL deficiency is associated with severe atherosclerosis [72,73], but in Africa, where 
the prevalence of MBL deficiency amounts to 30%, overall incidence of atherosclerosis 
is low and a possible association with MBL has not been studied [74]. 
    If MBL protects against severe atherosclerosis, which mechanism is involved and what 
does that tell us about the physiological function of MBL? Does MBL resemble surfactant 
protein D (SP-D) in its function as a mediator in lipid homeostasis [75]? One might 
speculate that MBL removes lipid particles involved in atherosclerosis from the 
bloodstream, which may be in line with findings that MBL can act as a scavenger 
molecule participating in clearance of dying host cells [30,31]. One may also 
hypothesize that lipid particles activate MBL, which are then removed from the 
circulation via opsonization and degradation in a target organ like the liver. In plants, 
mannose- and N-acetylglucosamine-specific lectins may be involved in the transport 
and/or accumulation of storage compounds [76]. Another interesting fact is that some 
plant lectins are potent antilipolytic agents [77]. 
    In conclusion, complement deficiencies may help unravel the physiological functions 
of the individual complement components or of the complement activation pathways as 
a whole. 
 
 
1.7 Introduction to this thesis  
 
The thesis comprises the next chapters and addresses the following research questions: 
 
Chapter 1.  General introduction 
 
This first chapter introduces the subject and the players in the field of the body 
defense  against infectious and chronic disease(s), and puts the complement 
system in historical perspective. 
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Chapter 2.  A case of familial meningococcal disease due to deficiency in 
mannose-binding lectin (MBL)  
(The Proceedings of the 2nd Eijkman Symposium on Tropical Diseases: From Molecule 
to Bedside. Marzuki S, Verhoef, J, Snippe H, eds; Kluwer/Plenum 2003) 
 
This overview explains how patient-related findings open new horizons, as this was 
the case with meningococcosis and the lectin complement activation pathway. 
 
Chapter 3. Prevalence of abnormal serum MBL levels in the Dutch population 
 
In this study, we investigated, by use of a competitive ELISA, the prevalence of 
MBL deficiency in the normal Dutch population. For this study, we used a 
representative panel of 419 randomly chosen serum samples from donors to the 
blood bank, and from young and elderly orthopedic patients visiting the out-
patient department. The ages of these serum donors ranged from 3 to 85 years. 
 
Chapter 4. A functional microtiter assay for MBL in human serum 
(Journal of Immunological Methods 2002; 268: 149-157) 
 
In this chapter, we describe the details of a functional MBL assay devised to 
estimate functional MBL levels (including MASP activity) in large panels of human 
sera. The assay devised is based on the principle of yeast (Saccharomyces 
cerevisiae)-induced activation of MBL and the subsequent bystander hemolysis of 
chicken erythrocytes used as ‘innocent bystander cells’ in the assay.  
    
Chapter 5.  Differential microorganism-induced MBL activation 
(FEMS Immunology and Medical Microbiology 2003; 36: 33-39) 
 
This study describes the use of the hemolytic MBL assay, as described in chapter 
4, to compare the strength of MBL activation by different bacteria and yeasts. 
Unexpectedly, in the case of two Neisseria meningitidis type B and C strains, less 
than one colony-forming unit (CFU) was still able to generate hemolysis. This 
seemingly homeopathic result could be explained by spontaneous meningococcal 
‘blebs’ formation, and subsequent MBL activation by these particles. Clinically, this 
result may play an important role in invasive meningococcal disease. 
Mycobacterium bovis BCG was another potent activator. Gram-negative bacilli 
like Pseudomonas aeruginosa and Legionella pneumophila could activate MBL, 
but only in higher microbial  concentrations.  
 
Chapter 6. Deficiency of MBL is a novel risk factor for legionellosis 
 
Legionella pneumophila is an intracellular bacterium that can survive and 
replicate in monocytes and macrophages. Does MBL have a protective role in 
legionellosis or does it augment susceptibility to this serious infection? Functional 
MBL titers were studied in sera from 124 proven and probable cases of 
legionellosis from the Bovenkarspel outbreak in the Netherlands in 1999, as well 
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as in sera from 60 individuals who had been exposed to the Legionella 
pneumophila type 1 outbreak in without developing clinical disease. Results were 
compared to those of 389 controls from the Dutch population. 
 
Chapter 7. The ‘immune adherence ‘phenomenon: a versatile imune transport and 
elimination system? 
 
The ‘immune adherence’ phenomenon, which describes the adherence of 
opsonized (C3b-laden) particles to erythrocytes via the C3b receptor (CR1), thus 
enabling transport of particles to the fixed elimination organs, is discussed in this 
chapter. Particles known to be opsonized are immune complexes and microbes, 
but additional experiments using the functional MBL assay show that lipoproteins 
are also capable of activating the complement system. Reduced opsonization not 
only leads to reduced clearance of infectious particles and immune complexes, 
thus enhancing infectious susceptibility and autoimmune disease, but it may also 
play a role the clearance of other particles including the primary lipoproteins 
chylomicrons and very-low density lipoprotein (VLDL) from the circulation.  
 
Chapter 8. A genetic link between systemic lupus erythematosus (SLE) and thyroid 
autoimmunity? 
 
In this study, we present a closer look at a family around a 13-year old girl with 
the first signs of the non-organ-specific autoimmune disease systemic lupus 
erythematosus (SLE). In her serum, extremely low levels of C4 were detected. In 
collaboration with our American colleague Dr. Chack-Yung Yu from Columbus 
(Ohio, USA), we studied the C4A allotypes in the affected subject and and found 
out that the quantity of C4A in her serum was zero (C4AQ0), although she had 
inherited a single C4B gene from each parent. In five family members on the 
maternal side, thyroid autoimmune disease had been diagnosed. Partial C4A 
deficiency was found in these individuals as well. This chapter offers insight into 
the complex discussion in the field of autoimmune diseases linked to deficiency of 
complement factor C4A.   
 
Chapter 9. General discussion.  
      A summary of findings is given, including suggestions for further research.  
 
 
 25
REFERENCES 
 
1. Walport, M.J. Complement. First of two parts. N Eng J Med 2001; 344: 1058-1066. 
2. Delves, P.J., Roitt, I.M. The immune system. First of two parts. N Engl J Med 2000; 343: 37-
49.    
3.  Medzhitov, R., C. Janeway. Innate immunity. N Eng J Med 2000; 343: 338-344. 
4.  Courtney Smith, L., K. Azumi, M. Nonaka. Complement systems in invertebrates. The ancient 
alternative and lectin pathways.  Immunopharmacol 1999; 42: 107-120. 
5.  Fearon, D.T., R.M. Lockley. The instructive role of innate immunity in the acquired immune 
response. Science 1996; 272:50-3. 
6.  Nelson, R.A. The immune-adherence phenomenon. Science 1953; 118: 733-737. 
7.  Cornacoff, J.B., L.A. Hebert, W.L. Smead, M.E. van Aman. Primate erythrocyte-immune 
complex-clearing mechanism. J Clin Invest 1983; 71: 236-247. 
8.  Davis, L.J., H.C. Brown. The adhesion phenomenon, a specific serological reaction occurring in 
trypanosomiasis. Trans Royal Soc Trop Med 1927; 21: 113. 
9.  Siegel, I., T.L. Liu, N Gleicher. The red-cell immune system. Lancet 1981; 2: 556-559. 
10.  Nelson, D.S. Immune-adherence. Adv Immunol 1963; 3: 131.  
11.  Miller, G.W., A.D. Steinberg, I. Green, V. Nussenzweig. Complement-dependent alterations 
in the handling of immune complexes by NWZ/W mice. J Immunol 1975; 114: 1166-1170.  
12.  Law, S.K.A., K.B.M. Reid. Complement in focus, 2nd edition. 1995. Oxford University Press. 
Oxford, GB. 
13.  Kuhlman, M., Joiner, K., Ezekowitz, R.A.B. The human mannose-binding protein functions as 
an opsonin. J Exp Med 1989; 169: 1733-1745. 
14.  Ohtani, K., Y. Suzuki, S. Eda, T. Kawai, T. Kase, T. Shimada, H. Keshi, Y. Sakai, A. Fukuoh, 
T. Sakamoto, N. Wakamiya. Molecular cloning of a novel human collectin from liver (CL-L1). 
J. Biol. Chem. 1999; 13681-13689. 
15.  Ohtani, K., Y. Suzuki, S. Eda, T. Kawai, T. Kase, H. Keshi, Y. Sakai, A. Fukuoh, T. 
Sakamoto, H. Itabe, T. Suzutani, M. Ogasawara, I. Yoshida, N. Wakamiya. The membrane-
type collectin CL-P1 is a scavenger receptor on vascular endothelial cells. J Biol Chem 2001; 
276: 44222-44228. 
16.  Holmskov, U.L. Collectins and collectin receptors in innate immunity. APMIS 2000; Suppl 100: 
1-59. 
17. Hansen, S., D. Holm, L. Vitved, C. Bendixen, K.B.M. Reid, K. Skjoedt, U. Holmskov. 
Abstract I-6. Proceedings of the Vth International Workshop on C1, the first component of the 
complement system, and collectins. 2001. 
18.  Hansen, S., M. Dahl, C. Stover, N. Lynch, S. Thiel, J.C. Jensenius, W. Schwaeble. Abstract 
III-3. Proceedings of the Vth International Workshop on C1, the first component of the 
complement system, and collectins. 2001. 
19.  Thiel, S., T. Vorup-Jensen, C.M. Stover, W. Schwaeble, S.B. Laursen, K. Poulsen, A.C. 
Willis, P. Eggleton, S. Hansen, U. Holmskov, et al. A second serine protease associated with 
mannan-binding lection that activates complement. Nature 1997; 386: 506-510. 
20.  Matsushita, M., T. Fujita. Cleavage of the third component of complement (C3) by mannose-
binding protein-associated serine protease (MASP) with subsequent complement activation. 
Immunobiol 1995; 194: 443-448.  
21.  Matsushita, M, S. Thiel, J.C. Jensenius, I.Terai, T. Fujita. Proteolytic activities of two types of 
mannose-binding lectin-associated serine protease. J Immunol 2000; 165: 2637-2642. 
22.  Stover, C.M., S. Thiel, M. Thelen, N.J., Lynch, T. Vorup-Jensen, J.C. Jensenius, W 
Schwaeble. Two constituents of the initiation complex of the mannan-binding lectin activation 
pathway of complement are encoded by a single structural gene. J Immunol 1999; 162:3481-
3490. 
23.  Takahashi, M., Y. Endo, T. Fujita, M.  Matsushita. A trncated form of mannose-binding lectin-
associated serine protease (MASP)-2 expressed by alternative polyadenylation is a component 
of the lectin complement pathway. Int Immunol  1999; 11: 859-863. 
 26
24.  Dahl, M.R., S. Thiel, M. Matshushita, T. Fujita, A.C. Willis, T. Christensen, T.Vorup-Jensen, 
J.C. Jensenius. MASP-3 and its association with distinct complexes of the mannan-binding lectin 
complement activation pathway. Immun 2001; 15:127-135. 
25.  Turner, M.W. Mannose-binding lectin: the pluripotent molecule of the innate immune system. 
Immunol Today 1996; 17: 532-540. 
26.  Emmerik, L.C. van, Kuijper, E.J., Fijen, C.A.P.,  Dankert, J., Thiel, S. Binding of mannan-
binding protein to various bacterial pathogens of meningitis. Clin Exp Immunol 1994;  97: 411-
416. 
27.  Neth, O., D.L. Jack, A.W. Dodds, H. Holzel, N.J. Klein, M.W. Turner. Mannose-binding 
lectin binds to a range of clinically relevant microorganisms and promotes complement 
deposition. Infect Immun 2000; 68: 688-693. 
28.  Roos, A., L.H. Bouwman, D.J. van Gijlswijk-Janssen, M.C. Faber-Krol, G.L. Stahl, M.R. 
Daha. Human IgA activates the complement system via the mannan-binding lectin pathway. J 
Immunol 2001; 167: 2861-2868. 
29.  Ghiran, I., S.F. Barbashov, L.B. Klickstein, S.W. Tas, J.C. Jensenius, A. Nicholsen-Weller. 
Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med 2000; 
192:1797-1807. 
30.  Ogden, C.A., deCathelineau, A., Hoffmann, P.R., Bratton, D., Ghebrehiwet, B., Fadok, 
V.A., Henson, P.M. C1q and mannose-binding lectin engagement of cell surface calreticulin 
and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194: 
781-795. 
31.  Raaschou-Jensen, N., H.O. Madsen, L.P. Ryder, C. Koch, P. Garred. Mannose-binding lectin 
tags cells undergoing apoptosis. Abstract IV-9. Proceedings of the Vth International Workshop 
on C1, the first component of the complement system, and collectins. 2001. 
32.  Pillemer, L., L. Blum, I.H. Lepow, O.A. Ross, E.W. Todd, A.C Wardlaw. Science 1954; 120: 
279-284. 
33.  Lepow, I.H, F.S Rosen. Pathways to the complement system. N Engl J Med 1972; 286: 942-
943. 
34.  Vorup-Jensen, T., Petersen, S.V., Hansen, A.G., Poulsen, K., Swaeble, W., Sim, R.B., Reid, 
.B.M., Davis, S.J., Thiel, S., Jensenius, J.C. Distinct pathways of mannan-binding lectin (MBL) 
and C1-complex autoactivation revealed by reconstitution of MBL with recombinant MBL-
associated serine protease-2. J Immunol 2000; 165: 2093-2100. 
35.  Klickstein, L.B., S. Barbashov, T. Liu, R.M. Jack, A. Nicholson-Weller. Complement receptor 
type 1 (CR1, CD35) is a receptor for C1q. Immun 1997; 7: 345-355. 
36.  Matsushita, M., T. Fujita. Inhibition of mannose-binding protein-associated serine protease 
(MASP) by C1 inhibitor. Mol Microbiol 1996; 33(S1): 44. 
37.  Terai, I., K. Kobayashi, M. Matsushita, T. Fujita, K. Matsuno. α2-Macroglobulin binds to and 
inhibits mannose-binding protein-associated serine protease. Int Immunol 1995; 7:1579-1584. 
38.  Storgaard, P., D. Holm, E. Nielsen, E. Skriver, O. Andersen, S.E. Svehag. Mannan-binding 
protein forms complexes with α2-macroglobulin. A proposed model for the interaction. Scand J 
Immunol 1995; 42: 373-380. 
39.  Armstrong, P.B., J.P. Quigley. α2-Macroglobulin: an evolutionary conserved arm of the innate 
immune system. Dev Comp Immunol 1999; 23: 375-390. 
40.  Petersen, S.V., S. Thiel, L. Jensen, T. Vorup-Jensen, C. Koch, J.C. Jensenius. Control of the 
classical and the MBL pathway of complement activation. Mol Immunol 2000; 37: 803-811. 
41.  Wong, N.K.H., M. Kojima, J. Dobó, G. Ambrus, R.B. Sim. Activities of the MBL-associated 
serine proteases (MASPs) and their regulation by natural inhibitors. Mol Immunol 1999; 36: 
853-861. 
42.  Suankratay, C., C. Mold, Y. Zhang, T.F. Lint, H Gewurz. Mechanism of complement-
dependent hemolysis via the lectin pathway: role of the complement regulatory proteins. Clin 
Exp Immunol 1999; 117: 442-448. 
43.  Suankratay, C., Mold, C., Zhang, Y., Potemba, L.A., Lint, T.F., Gewurz, H. Complement 
regulation in innate immunity and the acute-phase response: inhibition of mannan-binding lectin-
initiated complement cytolysis by C-reactive protein. Clin Exp Immunol 1998; 113: 353-359. 
 27
44.  Hourcade, D., M.K. Liszewski, M. Krych-Goldberg, J.P Atkinson. Functional domains, 
structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharmacol 
2000; 49: 103-116. 
45.  Hebert, L.A. The clearance of immune complexes from the circulation of man and other 
primates. Am J Kidney Dis 1991; 17: 353-361. 
46.  Tas, S.W., L.B. Klickstein, S.F. Barbashov, A. Nicholson-Weller. C1q and C4b bind 
simultaneously to CR1 and additively support erythrocyte adhesion. J Immunol 1999; 163: 
5056-5063. 
47.  Sunyer, J.O., I.K. Zarkadis, J.D. Lambris. Complement diversity: a mechanism for generating 
immune diversity? Immunol Today 1998; 19: 519-523. 
48.  Nonaka, M., T. Fujii, T. Kaidoh, S. Natsuume-Sahai, M. Nonaka, N. Yamaguchi, M. 
Takahashi. Purification of a lamprey component protein homologous to the third component of 
mammalian complement system. J Immunol 1984; 133: 3242-3249. 
49.  Nonaka, M. Evolution of the complement system. Curr Opin Immunol 2001; 13: 69-73. 
50.  Sunyer, J.O., L. Tort. Natural hemolytic and bactericidal activities of sea bream (Sparus aurata) 
serum are affected by the alternative complement pathway. Vet Immunol Immunopathol 1995; 
45: 333-345. 
51.  Zarkadis, I.K., D. Mastellos, J.D. Lambris. Phylogenetic aspects of the complement system. 
Dev Comp Immunol 2001; 25: 745-762. 
52.  Koppenheffer, T.L. Serum complement component of ectothermic vertebrates. Dev Comp 
Immunol 1987; 11: 279-286. 
53.  Krushkal, J., O. Bat, I. Gigli. Evolutionary relationships among proteins encoded by the 
regulator of complement activation gene cluster. Mol Biol Evol 2000;  17: 1718-1730 
54.  Nair, S.V., S. Pearce, P.L. Green, D. Mahajan, R.A. Newton, D.A. Raftos. A collectin-like 
protein from tunicates. Comp Biochem Physiol 2000;125: 279-289. 
55.  Courtney Smith, L., L.A. Clow, D.P. Terwilliger. The ancestral complement system in sea 
urchins. Immunol Rev 2001; 180: 16-34. 
56.  Dodds, A.W. Which came first, the classical/lectin pathway or the alternative pathway of 
complement? Abstract I-3. Proceedings of the Vth International Workshop on C1, the first 
component of the complement system, and collectins. 2001. 
57.  Al-Sharif, W.Z., J.O. Sunyer, J.D.Lambris, L. Courtney Smith. Sea urchin coelomocytes 
specifically express a homologue of the complement component C3. J Immunol 1998; 160: 
2983-2997. 
58.  Nonaka, M., K Azumi. Opsonic complement system of the solitary ascidian, Halocynthia 
roretzi. Dev Comp Immunol 1999; 23: 421-427. 
59.  Vasta, G.R., M. Quesenberry, H.Ahmed, N. O’Leary. C-type lectins and galectins mediate 
innate and adaptive immune functions: their roles in the complement activation pathway. Dev 
Comp Immunol 1999; 23: 401-420. 
60.  Wilson, R., C.Chen, N.A. Ratcliffe. Innate immunity in insects: the role of multiple, endogenous 
serum lectins in the recognition of foreign invaders in the cockroach, Blaberus dicoidalis. J 
Immunol 1999; 162: 1590-1596. 
61.  Bentley, D.R. Structural superfamilies of the complement system. Exp Clin Immunogenet 1988; 
5: 69-80. 
62.  Quigley, J.P., P.B Armstrong. An endopeptidase inhibitor found in Limulus plasma: an ancient 
form of α2-macroglobulin. Ann NY Acad Sci 1983; 421: 119-24. 
63.  Pahler, S., B. Blumbach, I. Muller, W.E. Muller,. Putative multi-adhesive protein from the 
marine sponge Geodia cydonium: cloning of the cDNA encoding a fibronectin-, an SRCR-, and 
a complement control protein module. J Exp Zool 1998; 282: 332-43. 
64.  Endo, Y., M. Takahashi, M. Nakao, H. Saiga, H. Sekine, M. Matsushita, et al. Two lineages 
of mannose-binding lectin-associated serine protease (MASP) in vertebrates. J Immunol 1998; 
161:4924-30.  
65.   Matsushita, M., Y. Endo, M. Nonaka, T. Fujita. Complement-related serine proteases in 
tunicates and vertebrates. Curr Opin Immunol 1998; 10: 29-35.  
 28
66.  Wilson, J.G., E.E. Murphy, W.W. Wong, L.B. Klickstein, J.H. Weis, D.T. Fearon. 
Identification of a restriction fragment length polymorphism by a CR1 and cDNA that correlates 
with the number of CR1 on erythrocytes. J Exp Med 1986; 164: 50-9. 
67.  Reilly, B.D., Mold, C. Quantitative analysis of C4Ab and C4Bb binding to the C3b/C4b 
receptor (CR1, CD35). Clin Exp Immunol 1997; 110: 310-316. 
68.  Madsen, H.O., M.L. Satz, B. Hogh, A. Svejgaard, P. Garred. Different molecular events result 
in low protein levels of mannan-binding lectin in populations from southeast Africa and South 
America. J Immunol 1998; 161: 3169-75. 
69.  Garred, P., M. Harboe, T. Oettinger, C. Koch, A. Svejgaard. Dual role of mannan-binding 
protein in infections: another case of heterosis? Eur J Immunogenet 1994; 21: 125-31. 
70.  Garred, P., C. Richter, A.B. Andersen, H.O. Madsen, I. Mtoni, A. Svejgaard, J. Shao. 
Mannan-binding lectin in the sub-Saharan HIV and tuberculosis epidemics. Scan J Immunol 
1997; 46: 204-208.  
71.  De Miranda Santos, I.K.F., C.H.N. Costa, H. Krieger, M.F. Feitosa, D. Zurakowski, B. 
Fardin, R.B.B. Gomes, D.L. Weiner, D.A. Harn, R.A.B. Ezekowitz, and J.E. Epstein. Mannan-
binding lectin enhances susceptibility to visceral leishmaniasis. Infect Immun 2001; 69: 5212-
5215. 
72.  Madsen, H.O., V. Videm, A. Svejgaard, J.L. Svennevig, P. Garred. Association of mannose-
binding lectin deficiency with severe atherosclerosis. Lancet 1998; 352: 959-560. 
73.  Hegele, R.A., M.R. Ban, C.M. Anderson, J.D. Spence. Infection- susceptibility alleles of 
mannose-binding lectin are associated with increased carotid plaque area. J Invest Med 2000; 
48: 198-202. 
74.  Muna, W.F. Cardiovascular disorders in Africa. World Health Stat Q 1993; 46: 125-133. 
75.  Borregaard, N., P. Elsbach, T. Ganz, P. Garred, A. Svejgaard. Innate immunity:from plants to 
humans. Immunol Today 2000; 21: 68-70. 
76.  Van Damme, E.J.M., W.J. Peumans, A. Pusztai, S. Batdocz. Handbook of plant 
lectins:poperties and biomedical applications. John Wiley & Sons, Chichester, GB, 1997. 
77.  Ng, T.B., W.W. Li, Yeung, H.W. Int J Biochem 1989; 21: 149-155. 
  
 
Chapter 2 
 
 
 
 
 
A case of familial meningococcal disease due to 
deficiency in mannose-binding lectin (MBL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. Kuipers1, P.C. Aerts1, O.J.J. Cluysenaer2, A.K.M. Bartelink2, R.A.B. Ezekowitz3,  
W.A.Bax2, M.M.M. Salimans4, and  H. van Dijk1,4 
 
 
1Eijkman-Winkler Center for Microbiology, Infectious Diseases and Inflammation, 
University Medical Center, Utrecht, the Netherlands,  2Department of Internal 
Medicine, Meander Medical Center, Amersfoort,  3Department of Pediatrics, Harvard 
Medical School, Boston, MA, USA, 4Department of Medical Microbiology and 
Immunology, Meander Medical Center, Amersfoort,the Netherlands   
 
 
Adapted from: The Proceedings of the 2nd Eijkman Symposium on Tropical Diseases:  
From Molecule to Bedside. Marzuki S, J. Verhoef, H. Snippe (Eds); Kluwer/Plenum 2003 
 30
ABSTRACT 
 
A case of familial meningococcal meningitis is described, which involved a 18-year 
old boy, his mother, and his grandfather, all three suffering from meningococcal 
disease in young adolescence (17-19 y), albeit with one or two generations in 
between. By studying the genetic variants of MBL, we found out that the three 
family members described carried the B/D variant mbl genes instead of the 
homozygous mbl A/A trait. Serum MBL levels within the family varied from below 
0.15 µg per ml (for the B/D variant) up to 7.0 µg per ml, with 1.67 µg per ml as 
mean serum level of a control population (n= 419). In the normal population, 
incidental cases with serum levels of up to 13 µg-equivalents per ml were also 
observed, which occurred predominantly in elderly people and which are most 
likely to be explained by the acute-phase reactant behavior of MBL protein. 
 
 
    In the autumn of 1997 in the Netherlands, there was a small epidemic of type-C 
meningococcal disease that, more or less, overlapped the ‘bible belt’. The  disease was 
most active in and around a village called Nijkerkerveen, which was also the village of 
birth of our male index patient. The boy’s meningitis was well diagnosed and responded 
to treatment with penicillin, resulting in uneventful recovery. Laboratory investigations on 
his serum showed normal immunoglobulin levels, while complement levels (CH50, 
AP50, and  C1q, C3, C4A and C4B serum levels) were in the normal range as well, 
which suggests an undisturbed humoral defense including the hitherto known complement 
pathways, the classical and alternative complement pathways [1]. So far, however, the 
rationale behind the familial behavior of the disease remained obscure. 
 
    Two years later, the European Immunology Meeting was held in Amsterdam, where 
the last author of this paper happened to be one of the chairmen at the session on 
complement. At that occasion, connections between susceptibility to meningococcal 
disease and carriership of mannose-binding lectin (MBL) variant alleles were reported. 
These reports were the reason to reopen the familial meningitis case, now with the sole 
purpose to identify putative MBL variant alleles and matching decreased serum MBL 
levels. To this end, we developed a competitive ELISA making use of reagents kindly 
donated by coauthor Dr. R.A.B. Ezekowitz [1]. With this ELISA, MBL protein levels were 
found in the index family ranging from < 0.15 up to 7 µg MBL per ml, with a mean value 
of 1.67 µg/ml. 
 
    After this event, we decided to develop a functional microtiter assay for MBL, based 
on the principle of yeast-induced bystander lysis of chicken erythrocytes [2]. In this assay, 
live cells of Saccharomyces cerevisiae are used as activators of MBL, which give rise to 
C5b6-formation, that − together with terminal complement components C7, C8, and 
C9 − is able to lyse innocent bystander cells. For this purpose, we use chicken 
erythrocytes, but trypsin-treated guinea pig erythrocytes may be used as well. In this 
assay, serum deficient in MBL is used as reagent serum (R-MBL), for which we regularly 
employ serum of the mother of the index patient. Characteristics of the assay are a 
minimum detection level of 0.20 µg-equivalents MBL per ml, a linear relationship with 
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MBL mass (r = 0.869; p < 0.0001), and inhibition of hemolysis by C1-inhibitor (C1-
INH), but not by α2-macroglobulin, and by the sugars mannose, N-acetylglucosamine, 
and fucose, but not by galactose. 
 
    With the newly developed functional MBL assay, we were able to test a great many 
serum samples (over 5000), including those from young children with recurrent 
pneumococcal otitis media, young children with malignancies, a large family with 
recurrent furunculosis, and serum samples from individual cases with recurrent infections, 
frequent miscarriages, and atherosclerosis.  
 
Take-home message 
Ever since we met our case of familial meningococcal disease in the Netherlands, nothing 
remained the same:  
    We learned that the complement system does not only have two activation pathways, 
the classical complement activation pathway and the alternative complement activation 
pathway, but also a third one: the MBL-dependent ‘lectin complement activation 
pathway’, besides the terminal pathway, which is a short-cut between the three real 
activation pathways and one of the effector mechanisms of the complement system: the 
formation of membrane-attack complexes (MAC). The latter can kill certain gram-
negative microorganisms like Neisseria meningitidis. Moreover, phylogenetic studies by 
colleagues in the field have taught us that the lectin pathway is by far one of the most 
ancient pathways of the complement system, dating from at least 700 million years. The 
classical and terminal pathways, however, are much younger, originating from 450 
million years ago. Scientists in our field are now involved in studies which should tell us 
whether the lectin or the alternative pathway is the most ancient complement activation 
pathway. If the latter will be true, the lectin pathway may function as the initiator of the 
alternative complement pathway.  
 
    Since MBL is such an ancient molecule, there are also ill-functioning variant alleles, 
based on single-base substitutions that predestinate for serious (chronic) disease, 
including infections, autoimmunity, and atherosclerosis. However, variant alleles may 
also be protective, which holds especially true for the African (C-type) variant that 
protects from mycobacterial diseases like tuberculosis and leprosy. Tubercle bacilli are 
‘encapsulated’ by lipoarabinomannan (LAM), which is recognized by intact but not by 
variant MBLs, the latter of which do not allow activation of the lectin pathway. We 
presume that the leprosy bacterium carries a similar, capsule-like structure, which also 
helps to activate the lectin pathway resulting in opsonization by and ‘hiding’ of the 
phagocytosed bacteria in mononuclear phagocytes; the phenomenon involved in the 
chronicity of mycobacterial disease. The protective effect of variant MBLs, encoded for 
by a defective gene, may then be explained by the fact that they are unable to activate 
the MBL-associated serine proteinases (MASPs, which are molecules very much related 
to the C1q-associated C1r and C1s), preventing lectin pathway activation and thereby 
chronic disease with specific intracellular pathogens. 
 
    With help of our functional assay, we studied the prevalence of MBL deficiency in 
different populations. The incidence of MBL deficiency in the Dutch population was 
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established to be 13%, mostly due to the B and D variants, and LX promoter 
polymorphism. The prevalence of MBL deficiency in African countries is, however, about 
35%, which underlines again the importance of variant alleles in the resistance to 
mycobacterial disease.  
 
    Since MBL is independent of antibodies, one may speculate that the lectin pathway is 
the innate-immunity counterpart or even the predator of antibodies, as it is able to 
recognize sugar moieties on all type of microorganisms. Again with help of our functional 
assay, we tested the ability of different microorganisms to activate the lectin pathway [3]. 
The MBL-activating ability was expressed in number of microbes giving rise to a certain 
degree of activation (Z-value [number of active sites per target cell] = 0.6). The data 
obtained showed that again meningococci were the most powerful activators of the 
human lectin pathway, with less than one colony-forming unit giving rise to optimum 
lectin-pathway activation. 
 
    In conclusion, MBL is a very versatile protein that deserves very thorough study in 
order to elucidate its exact role in the defense from different pathogens and diseases. 
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ABSTRACT 
 
Mannose-binding lectin (MBL) is an ancient serum protein involved in the initiation of 
complement activation via the so-called lectin pathway (LCP). Since MBL activation is 
antibody-independent, the LCP is considered part of the non-specific (innate) immune 
system. Probably due to its antiquity, the mbl gene and/or its promoter region may 
contain several point mutations, with diminished function(s) of the protein in 
consequence of decreased oligomerization. In all age groups, defective genes are 
associated with an increased susceptibility of the carrier to infection. In MBL-deficient 
patients with cystic fibrosis, or those receiving chemotherapy or stem cell transplantation, 
infectious complications are more prevalent. From literature it is known that MBL 
deficiency is associated with severe atherosclerosis too. Therefore, for defined patient 
groups, MBL substitution therapy may well become common practice in the very near 
future. The purpose of the present study was to define normal and decreased MBL serum 
levels, and to establish the prevalence of MBL deficiency in a randomly chosen cross-
section of the multicultural Dutch population (n = 419; age 3-85 y). MBL deficiency 
was tested by a competitive, enzyme-linked immunosorbent assay making use of a 
commercially available peroxidase-labeled monoclonal anti-MBL antibody. In our study, 
individuals could be distinguished with decreased MBL levels (0.20-0.42 mg/L) in 9.1% 
of the study population, and ultra-low antigenic MBL levels (< 0.20 mg/L) in 3.1%, 
which occurred most frequently below the age of 60. From the age of 60 onwards, 7.8% 
of the donors presented with enhanced serum MBL levels. No significant correlation was 
established between C-reactive protein (CRP) and MBL levels, which makes it highly 
unlikely that high MBL levels are due to an acute phase response. 
 
 
INTRODUCTION   
 
    Mannose-binding lectin (MBL) is the leading protein in the lectin pathway of 
complement activation (LCP). The protein belongs to the family of C1q-related 
collectins, proteins consisting of trimeric subunits with a collagenous tail and globular 
sugar-binding domains [1]. MBL has affinity for mannose, N-acetylglucosamine, and 
fucose moieties on Gram-negative and Gram-positive bacteria [2-4], yeasts [3-5], 
parasites [6,7], and viruses [8,9].  
    The antibody-independent LCP is considered to be part of the innate immune system, 
able to respond to foreign invaders within minutes to hours. The main function of the LCP 
is the coating of microorganisms with C3b and/or C3bi, which makes these microbes 
vulnerable to phagocytosis and killing by polymorph nuclear cells and phagocytes of the 
mononuclear lineage [10].   
    Deficiencies of MBL are associated with all kinds of - mostly infectious - diseases. 
These include respiratory tract infections in early childhood [11], meningococcal disease 
[12,13], invasive pneumococcal disease [14], and severe infections complicating cystic 
fibrosis (CF) [15], chemotherapy [16,17] and stem cell transplantation [18]. Intriguingly, 
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MBL deficiency is also related to severe atherosclerosis, but the background of this 
linkage has not been satisfactorily explained yet [19]. Purified-MBL therapy has been 
given to young MBL-deficient patients [20], and it is highly probable that in the near 
future CF and cancer patients will be screened for MBL deficiency in order to reduce 
infectious complications during treatment [21].  
    The prevalence of MBL deficiency has been estimated in different study populations, 
both by antigenic and genetic means. Genetic studies show decreased MBL serum levels 
in the subjects with variant alleles B, C, and/or D as compared to the homozygous wild-
type A gene, and in promoter polymorphisms H/L, X/Y, and P/Q. So far, the largest 
population studied for serum MBL levels included over a thousand normal Japanese 
individuals ranging in age from 3 to 100 years [22]. Similar, but smaller studies have 
been performed in different populations around the world [23-29]. So far, the 
prevalence of MBL deficiency in the Netherlands was unknown.     
    The purpose of the present paper was to study the distribution of MBL serum levels in 
the Dutch multicultural population. To this end, a highly sensitive, competitive ELISA was 
used [12]. The genetic background of low MBL serum levels was studied by testing a 
selection of serum samples showing low and ultralow MBL levels for mbl gene mutations 
and promoter polymorphisms using an ultrasensensitive PCR applicable to serum instead 
of isolated DNA. By comparing MBL values with CRP levels, the putative impact of the 
acute phase response on serum MBL levels was studied.  
 
 
MATERIALS AND METHODS 
 
Sources and preparation of human sera. Human sera were collected from 419 
individuals. Sera were from healthy regular donors to a blood bank (age 18-65 years; n 
= 257), patients to an general pediatric outpatient department (age: 3-18 years, n = 
93; first visit), and pre-operative patients to an orthopedic outpatient department (age 
65-85 years; n = 69; first visit). The male to female sex ratio was 1.2: 1. The medical 
history of these individuals, e.g. the occurrence of MBL deficiency-associated diseases, 
was unknown. Informed consent was obtained from all individuals. All sera were stored at 
–70°C until further use. Two reference sera with MBL levels of 0.396 µg/ml and 1.25 
µg/ml were a kind donation by Dr. P. Garred (Tissue Typing Laboratory, Copenhagen, 
Denmark). 
MBL and anti-MBL antibodies. Purified MBL was a kind gift from Dr. Alan B. Ezekowitz, 
Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA. 
Peroxidase-labeled anti-MBL antibodies were commercially obtained (anti-MBL 
monoclonal antibody clone 131-1, Statens Serum Institute, Copenhagen, Denmark). 
Determination of MBL serum levels. Serum MBL levels were estimated by a protein-
specific competitive ELISA, which was executed as follows: high-binding ELISA plates 
(Costar, Corning, NY, USA) were coated with 1.5 mg MBL per ml. The coated wells 
were blocked with 2% protein hydrolysate (kindly donated by Dr. Glas, Friesland Dairy 
Foods, Leeuwarden, the Netherlands). Sera to be tested were serially (10–0.5) diluted. 
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Subsequently, mixtures were prepared consisting of 1/12,500-diluted horseradish-
peroxidase-labeled anti-MBL monoclonal antibody and serially diluted serum. Mixtures 
were allowed to incubate for one hour at room temperature. After each incubation step, 
the wells were thoroughly washed. Tetramethylbenzidine dissolved in acetic acid (pH = 
5.5) was used as the chromogenic substrate. Following substrate conversion, the reaction 
was stopped by 0.5 M H2SO4. Optical densities were read at 450 nm. The lower 
detection limit of the assay was established as 0.026 µg/ml. Serial dilutions of the 
reference sera (MBL levels of 0.396 and 1.25 µg/ml) were used as intermediate- and 
normal-level MBL references for the competitive ELISA in every run. 
Genotyping of MBL gene and promoter variants in sera with low MBL levels. The 
MBL genotypes of 29 out of 51 sera with decreased levels (≤ 0.42 µg/ml) were 
determined. DNA could be isolated from these serum samples according to the 
manufacturer’s instructions using an ultrasensitive, commercially available DNA isolation 
kit (QIAamp DNA Blood Mini Kit, Qiagen, Hilden, Germany). Genomic PCRs were 
performed in 50-µl volumes containing specific primers for the alleles in the exon 1 
region (B, C, and D variants, and wild-type A) and primers for the promoter region types 
H and L, X and Y of the mbl gene, as described previously by Madsen et al. [30]. Briefly, 
DNA was amplified by an initial general polymerase chain reaction, followed by site-
directed mutagenesis (SDM) PCR for the wild-type A, and the variant alleles types B, C, 
and D. Restriction-enzyme digestion of the PCR products was performed in order to 
distinguish between variant alleles. Promoter polymorphism types L, X, and Y, as well as 
the cis/trans locations of the promoter variants H/L and X/Y relative to the structural 
variants were determined as described by Madsen et al. [30]. For the detection of 
promoter polymorphism type H, primer 5’-TTA-CCC-AGG-CAA-GCC-TGT-G-3’ was 
used in 40 cycles of 30 sec at 94C, 60 sec at 68 C, and 60 sec at 72C.  
Determination of the correlation between CRP and MBL in a subpopulation. In 40 
randomly chosen sera, MBL values (in µg/ml) were determined and compared with CRP 
levels in the same sample. CRP (in mg/L) was determined by analysis on a BNII 
nephelometer (Dade Behring, Darmstadt, Germany). 
Statistical analysis. Mean MBL levels in the study population were determined by 
calculating the arithmetic and geometric means of all samples. The median was defined 
as the MBL levels of the 210th sample in the MBL-level-ranked study population. Age-
related reference centiles were constructed according to Altman [31]. Briefly, after 
modeling the mean as a function of age, the age-specific standard deviation was 
estimated by regressing the absolute residuals on age, with the assumption that the data 
were, or could be transformed to be, normal at each age using the properties of the half 
normal distribution. The Pearson correlation coefficient r was used to correlate MBL and 
CRP serum levels.  
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RESULTS 
 
    The frequency of reduced serum MBL levels in the Dutch population was investigated 
using a competitive ELISA using recombinant MBL and monoclonal anti-MBL antibody 
as coating and developing agents, respectively. Sera tested were from a representative 
cross-section through the Dutch population with donors in the age range from 3 to 85 
years (n = 419; average age: 40.8 years). 
 
 
Figure 1.  A scatter plot of MBL levels in serum from Dutch subjects (n = 419) as measured by 
competitive ELISA.   The age (years) is given on the x-axis, while serum MBL levels (in µg/ml) are shown 
on the y-axis. A line representing the arithmetic mean (MBL level: 1.67 µg/ml) is superimposed in the 
figure. 
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    Individual serum MBL levels ranged from 0.026 to 13.5 µg/ml. The geometric mean 
of the whole study population amounted to 1.15 µg/ml, while the median and arithmetic 
means were 1.27 and 1.67 µg/ml, respectively. Upon exclusion of values below 0.42 
µg/ml, representing MBL-deficient sera, the median and arithmetic means were 1.45 and 
1.88 µg/ml, respectively. A scatter plot of MBL levels, on which the arithmetic mean was 
superimposed, is shown in Fig. 1. When age-related reference centiles were constructed 
using absolute residuals [31] (Fig. 2), no significant correlation was found between log 
MBL levels and age.  
    Fig. 3 shows the frequency distribution of logarithmically ranked MBL serum levels. 
The overall pattern of MBL levels did not meet the criteria of a normal distribution, but 
rather that of a distribution with maxima at 0.07, 0.32, and 1.78 µg MBL/ml. The first 
group consisted of undetectable MBL serum levels (< 0.20 µg/ml), the second group of 
diminished MBL levels (between 0.20 and 0.42 µg/ml), and a third group of normal MBL 
levels (> 0.42 µg/ml).  
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Figure 2. MBL serum levels in 419 subjects in the age of 3 to 85 years: age-related reference centiles 
using absolute residuals, according to the method of Altman. No significant positive or negative 
correlation could be established between log MBL levels and age. 
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Figure 3. Frequency distribution of MBL in human sera (n = 419). MBL values are given on a logarithmic 
scale on the abscissa. On the y-axis, the number of individual serum samples is shown. Serum MBL levels 
could be divided into 3 distinct subgroups: MBL levels below 0.20 µg/ml, MBL levels between 0.20 and 
0.42 µg/ml, and MBL levels higher than 0.42 µg/ml. 
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    Fifty-one individuals (12.2 %) showed serum MBL levels below 0.42 µg/ml, of which 
thirteen individuals showed MBL levels below 0.20 µg/ml (3.1% of population). Clearly 
enhanced MBL levels were found in eight donors in the age range of 60 to 85 years (2% 
of population; 7.8% of donors > 60 years; MBL > 7.5 µg/ml). In order to exclude that 
high MBL levels were infection-related, a comparison was made between MBL and CRP 
levels in 40 randomly selected sera (MBL range between 0.166 and 7.256 µg/ml). A 
weak negative correlation (r = - 0.11) was found between serum MBL and CRP levels 
(Fig. 4). 
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Figure 4. Scatter plot showing a weak, inverse correlation (r = - 0.11) between MBL and CRP levels in 
serum. The correlation was not significant. CRP is a well-known acute phase reactant, whereas MBL 
shows a weak response in the acute phase.  
 
 
    Sera showing decreased MBL levels (< 0.42 µg/ml) were investigated for codon 
mutations of the mbl gene and for promoter polymorphisms H/L and X/Y (Table 1). In 
this subpopulation (n = 29), 11 individuals bore the wild-type A/A genotype combined 
with promoter polymorphisms of mainly the LX type (8 out of 11). The heterozygous 
wild-type genotypes A/B and A/D were present in ten and five out of 29 subjects, 
respectively. 
    The homozygous variant allele B/B genotype with LY promoter polymorphism was 
established in 2 out of 29 individuals. No codon 57 mutation (type C) was observed in 
our MBL-deficient subpopulation. LXA/HYA (24%), and LXA/LYB (21%) genotypes 
were found throughout the range between 0.026 and 0.381 µg/ml, while the 
LXA/DHY genotype was found in the MBL range of 0.246 and 0.381 µg/ml. The X 
allele was found only in combination with L, the LY haplotype only with the B variant, 
while the D variant was found only in combination with HY, which is in line with linkage 
disequilibrium data published by Madsen et al. [25]. 
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Table 1. Low-level MBL sera were investigated for the presence of codon variants type B, C, and D, 
according to increasing MBL levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
    This study aimed at investigating serum MBL levels in a representative cross-section of 
the Dutch population in which, so far, a large-scale study had not been conducted. In 
literature, MBL deficiency has been associated with increased susceptibility to several 
infectious and non-infectious diseases [11-19]. Measuring MBL levels in defined patient 
populations is becoming increasingly interesting, since MBL substitution therapy is 
currently under development (personal communication; Garred, 2002).  
    In our study, antigenic MBL serum levels could be divided into three subgroups, 
including a low-level group (< 0.20 µg/ml), an intermediate group with MBL levels 
ranging from 0.20 to 0.42 µg/ml, and an MBL-sufficient group (MBL > 0.42 µg/ml). In 
the distribution profile no age-dependency was found, even when values were 
transformed into residuals according to Altman [31]. Age variation in the serum MBL 
concentration, as described in Finnish children younger than 12 years [32], was not 
MBL serum level (µg/ml) MBL genotype 
0.026 LXA / HYA 
0.039 LXA / LXA 
0.054 LYB / LYB 
0.055 LYB / LYB 
0.060 LXA / HYA 
0.070 LYA / LYB 
0.104 LXA / LYA 
0.181 HYA / HYA 
0.216 LXA / LYB 
0.217 LXA / LYB 
0.229 HYA / LYB 
0.237 LXA / LYB 
0.245 HYA / HYD 
0.246 LYA / HYD 
0.254 LXA/ HYD 
0.258 LXA / HYA 
0.272 LYB / LYB 
0.275 LYB / HYD 
0.278 LXA / LYB 
0.290 LXA / LYB 
0.296 LXA / HYA 
0.299 LXA / LYB 
0.311 LYA / HYA 
0.312 LXA / HYA 
0.343 LXA / HYA 
0.349 LYA /  HYD 
0.358 HYA / HYA 
0.366 HYA / LYB 
0.381 LXA / HYD 
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confirmed by our study. However, our results indicated that maximum MBL levels per 
age category tended to increase with age. Very high MBL levels (> 7.5 µg/ml) were 
limited to people over the age of sixty.  
    Our findings are at variance with data from the Japanese population, which showed 
declining values with advancing age, the highest values being found in the age group of 
3 to 9 years [22]. Our data are comparable to values in a group of 123 Danish blood 
donors, in which the median MBL serum level was 1.23 µg/ml, and 13% non-A/A 
genotypes MBL were found [29]. A striking finding was the decreasing number of donors 
with very low MBL levels (< 0.20 µg/ml) with increasing age. This is in agreement with 
the observation that MBL-deficient individuals are more prone to infection and to serious 
inflammatory diseases like atherosclerosis.  
    Besides as complement component, MBL has been described as a mild acute-phase 
reactant, doubling or tripling MBL serum levels [33,34]. In a second Finnish study, serum 
MBL levels in MBL-deficient patients with bacterial infection remained undetectable, 
while mean MBL levels in patients with documented bacterial infections were 
significantly higher than in healthy controls (9.88 versus 4.48 µg/ml) [32]. In the latter 
study, C-reactive protein (CRP) showed a significant though weak negative correlation 
with MBL. However, in a recent study in HIV-positive patients, no correlation was found 
between CRP and MBL [35]. By comparing CRP levels to MBL levels in our study 
population, we established a weak but non-significant correlation between the two 
variables, thereby excluding acute bacterial infection in this group (Fig. 4).  
    The genetic basis for MBL deficiency codon mutations is found in exon 1 of the mbl 
gene on chromosome 10. Single-base substitutions, found at codons 52, 54, and 57, are 
indicated as variant alleles D, B, and C, respectively. MBL of wild-type structural gene 
homozygotes include MBL dimers, trimers, tetramers and oligomers. MBL oligomers, 
which are particularly effective in complement activation [36], are absent or diminished 
in individuals with codon mutations. Point mutations also lead to distortion of the 
collagen helix of the protein [37].  
    Changes in the dimorphic loci in the promoter region of the MBL gene may also 
influence MBL levels, though to a much lesser degree than the codon variants 
[10,38,39]. Promoter polymorphisms are called H (high) versus L (low), X versus Y (Y 
leading to higher MBL levels than X), and P versus Q. Since P promoter polymorphism is 
part of both high-expressing and low-expressing haplotypes, studying P/Q polymorphism 
as such does not provide additional information [25]. Only the LX haplotype down-
regulates MBL as efficiently as a structural variant. In a very recent paper, other 
promoter polymorphisms have been described [28], and it may well be that more minor 
aberrations will be uncovered in the near future. 
    In our study, human serum was the only source available for MBL genotyping. 
Normally, upon centrifugation, a minute amount of genetic material is released from 
nucleated cells, enabling amplification for genotyping. In some serum samples, very low 
amounts of DNA were detected, necessitating a second PCR with the same primer sets 
on the PCR product from the first run.  
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    Genotyping was performed in a subpopulation of subjects with low MBL levels (n = 
29; Table 1). The heterozygous, wild-type genotypes A/B and A/D were present in 10 
and 5 out of 29 subjects, respectively, while one individual showed a B/D genotype. The 
homozygous variant allele B/B genotype could be established in 2 out of 29 individuals 
with low MBL levels. LYB haplotypes were found in 13 out of 29 low-level sera. Type B 
mutant is the most frequently found gene mutation in the Caucasian population (0.11-
0.16), while type D mutant occurs at less than 0.05 all over the world [10]. No codon 
57 mutation (type C) was observed in our MBL-deficient subpopulation, indicating that 
no one of African decent had participated in this randomly chosen study population. In 
11 individuals, the wild-type A/A genotype was found combined with promoter 
polymorphisms of mainly the LX type (8 out of 11), compared to the LY and HY type. In 
Caucasoids, the LXA and LYA haplotypes are less frequent (24 and 23% respectively) 
than the high MBL-producing HYA haplotypes (33%).  
    Our results show that over 12% of the present Dutch population has decreased serum 
MBL levels. This percentage is in the same order of magnitude as described in Denmark 
and the United Kingdom. In a recent study with a different study population (n = 121), 
we showed that functional MBL levels in serum correlated significantly to ELISA levels (r 
= 0.869) [40], suggesting that MBL function is diminished in individuals with variant 
alleles or promoter polymorphisms. 
    In conclusion, we were able to establish normal MBL levels and to quantify decreased 
MBL levels as a measure of deficiency. In our study, over 12% of the Dutch population 
was typed MBL-deficient. Defining MBL levels in patients is becoming more and more 
important since decreased MBL serum levels, which cause increased susceptibility to 
infection and to inflammatory diseases like atherosclerosis, may be treatable in the very 
near future. 
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Abbreviations 
AP50  : hemolytic alternative pathway activity 
CH50  : hemolytic overall complement activity 
ChE  : chicken erythrocytes 
C1-INH : C1 esterase inhibitor 
EDTA  : ethylene diamine tetraacetic acid 
EGTA  : ethylene glycol bis-(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid 
ELISA  : enzyme-linked immunosorbent assay 
HPS  : human pooled serum 
MAp19 : MBL-associated protein of 19 kDa 
MASP  : MBL-associated serine proteinase 
MBL  : mannose-binding lectin 
MoAb  : monoclonal antibody 
PMN  : polymorphonuclear granulocyte  
VBS  : veronal-buffered saline  
 
 
ABSTRACT 
 
A simple assay was developed to estimate functional mannose-binding lectin (MBL) 
levels in serum, based on the principle of yeast-induced bystander lysis of chicken 
erythrocytes. The assay is sensitive to inhibition by EGTA (which allows alternative 
pathway activation), EDTA, mannose, N-acetylglucosamine and C1 esterase inhibitor 
(C1-INH), whereas it was not inhibited by galactose. A high-titer human anti-mannan 
antibody-containing serum with 0.06 µg MBL per ml gave a functional signal 
corresponding to 0.12 µg-equivalents MBL per ml, indicating that anti-mannan 
antibodies are poorly hemolytic in the assay. The assay is well suited for the large-scale 
testing of patient samples for a functional MBL activity. 
 
 
INTRODUCTION 
 
    Mannose-binding lectin (MBL) is a high-molecular-weight protein present in blood 
plasma at low concentrations (1.7 µg/ml). Together with the human proteins CL-L1 [1], 
CL-P1 [2], and lung surfactant proteins A and D, and the bovine proteins conglutinin, 
collectin-43 [3] and collectin-46 [4], the protein belongs to the family of C1q-related  
‘collagenous lectins’ (collectins). MBL is the first component of the lectin pathway (LP) of 
complement activation and binds microorganisms and foreign particles via specific sugar 
residues (mannose, N-acetylglucosamine, and fucose) by its three identical lectin 
moieties, thereby acting as an opsonin [5]. When foreign bodies are bound by MBL, 
three MBL-associated proteins (MASP-1, MASP-2, and MAp19) [6-9] become 
coordinately activated, resulting in the generation of the active form of MASP-2, the LP-
dependent C4/C2 convertase. The role of a recently discovered, fourth MBL-associated 
protein (MASP-3) probably involves downregulation of MASP-2 as shown by in-vitro 
experiments [10]. Substrate-bound C4bC2a is a C3 convertase, which allows the 
conversion of C3 into C3a and C3b, the key reaction leading to terminal-pathway 
initiation. Besides indirect C3 activation, the lectin pathway may also be involved in 
direct C3 activation [11]: MASP-1 can cleave C3 independently [12]. An ex-vivo 
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model has shown that MBL decreases pro-inflammatory cytokine production in 
meningococcal disease [13]. 
    MBL deficiencies are quite common in man. In fact, low-level haplotypes can occur in 
up to 30% of the human population [14], and are associated with all kinds of infectious 
and infection-related diseases. MBL treatment of individuals with recurrent infections 
secondary to severe MBL deficiency has proven useful in certain cases [15], which 
strongly suggests that there is a future for MBL substitution therapy. The genetic basis of 
MBL deficiency is found in variant alleles and promotor polymorphisms. All mbl gene 
codon mutations are found in exon 1 on chromosome 10. Single-base substitutions, 
found at codons 52, 54, and 57, are indicated as the variant alleles D, B, and C, 
respectively. These variant alleles lower the serum MBL levels [15]. Changes in the 
promoter region of the MBL gene, called H (high), L (low), X, and Y, also have a 
profound impact on MBL serum levels, with LX leading to low MBL levels, LY to 
intermediate levels and HY to high levels. The P promotor polymorphism is found in both 
high- and low-expressing haplotypes; therefore an isolated search for the P/Q promotor 
polymorphism is probably not useful [16,17]. 
    Over the past twelve years, several enzyme immunoassays have been developed to 
estimate antigenic MBL levels in serum. One common disadvantage of these antigenic 
assays, however, is that they fail to measure functional MBL, i.e. the joint activity of the 
MBL-MASPs complex. Recently, functional MBL assays either based on the lysis of 
mannan-coated erythrocytes [18] or mannan-induced C4b-deposition were developed 
[19]. In the present paper, we describe a new hemolytic test for the estimation of 
functional MBL in serum and compare the data obtained with those from a competitive 
MBL ELISA presented earlier [20]. In short, the yeast Saccharomyces cerevisiae was used 
as an MBL activator in a dilution series of human serum, to which MBL-deficient serum 
was added as a source of all complement components except MBL. Chicken erythrocytes 
were used as the target for hemolysis. The influence of classical pathway activation by 
anti-mannan IgG antibodies on the outcome of the assay was studied using an MBL-
deficient serum with high anti-mannan antibody levels. MBL-specific oligosaccharides 
mannose and N-acetyl-D-glucosamine, but not galactose, substantially reduced 
hemolysis, which is in line with the idea that the former two sugars compete with yeast 
cells for MBL binding. The MBL regulatory function of C1 esterase inhibitor (C1-INH), 
which regulates the lectin pathway by binding to MASP-1 and MASP-2 in an equimolar 
manner [21] could be confirmed using our assay.  
 
 
MATERIALS AND METHODS 
 
Chemicals. D(+)-mannose (Mr 180.2) was obtained from Sigma, Zwijndrecht, the 
Netherlands (catalogue number M-4625), N-acetyl-D-glucosamine (GlcNAc; Mr 
221.2) from Serva, Heidelberg, Germany (catalogue number 10290), D(+)-galactose 
(Mr 180.2)  from Sigma (catalogue number G -0750), and C1-inhibitor from 
Calbiochem-Novabiochem Corp., La Jolla, CA, USA (1 mg/ml; catalogue number 
204883). 
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Buffers. VBS++: Veronal (5 mM)-buffered saline (VBS), pH 7.4, containing 0.15 mM 
Ca2+ and 0.5 mM Mg2+. EGTA-VB: VBS containing 8 mM EGTA and 2.5 mM Mg2+. 
EDTA-VB: VBS containing 10 mM EDTA. 
Human serum. Blood collected from 20 healthy coworkers at our laboratory and from 
121 donors to a blood bank was allowed to clot for 30 min, and was subsequently 
centrifuged at 1,500x g for 10 min. Individual samples were stored at -70˚C until further 
use. The sera from the laboratory workers were subsequently pooled (human pooled 
serum, HPS), and stored similarly. Serum from a subject known to have a very low MBL 
level [20] was used as the MBL-reagent serum in the functional assay. Serum with a high 
IgG anti-mannan antibody titer (IgG 8.7 mg/l, IgM 5.6 mg/l) from an MBL-deficient 
individual (antigenic MBL level of 0.06 µg/ml) was used to study the influence of anti-
mannan antibodies on very low MBL levels. Informed consent was obtained from all 
donors. 
Baker’s yeast. Saccharomyces cerevisiae cells were cultured on Sabouraud agar plates 
(Merck, Darmstadt, Germany) for 48 h at 37˚C before being used as lectin-pathway 
activators. Yeast particles were enumerated microscopically by the Thoma slide counting 
chamber method (W. Schreck, Hofheim, Germany). 
Functional assay for mannose-binding lectin. The functional MBL assay, based on the 
principle of MBL-dependent bystander hemolysis, was executed in U-well microtiter 
plates (Greiner, Frickenhausen, Germany). First, sera to be tested were serially diluted in 
the test plate in order to obtain 50-µl samples in a dilution series of 10–0.5 (1/10 to 
1/3,162), starting with a serum dilution of 10% in VBS++. Then, a 10-ml test mixture in 
VBS++ was prepared per microtiter plate. Such a mixture contained a standardized 
amount of freshly cultured baker’s yeast Saccharomyces cerevisiae (3.0 x 107 cells), 150 
µl reagent serum as a source of all complement components except MBL, and 109 
chicken erythrocytes (ChE) as the target cells of bystander hemolysis. Direct hemolysis of 
the erythrocytes induced by yeast cells was excluded by incubating the erythrocytes and 
yeast cells together just with reagent serum. Human pooled serum (MBL titer: 1.67 µg/ml 
as determined by ELISA [20] was used as the MBL reference sample in the assay.  
    A total of 100 µl of test mixture was added to each test well containing serum 
dilutions, and the microtiter plate was put on a water-based incubator operating at 37°C 
[22]. After incubation, the erythrocytes were spun down and 50-µl samples of each 
supernatant were transferred to a flat-bottom plate with 200-µl samples of water in each 
well. Hemoglobin release was measured in an ELISA reader operating at a wavelength of 
405 nm. Percentages of hemolysis were calculated using controls for 100% (water-
lysed) and 0% hemolysis (buffer control). The percentages were then transformed to the 
number of active sites per cell according to the equation published by Borsos and Rapp 
[23]:  
 
Z (number of active sites per cell) = -ln  (1 – fraction erythrocytes lysed)   
 
    Titers were read at Z = 0.200. Functional MBL titers were defined as titers in µg 
equivalents MBL per ml, relative to the known reference. Sera were also tested in EGTA-
VB to study alternative pathway activation and in EDTA that inhibits the three 
complement activation pathways. For this and all other results presented, a minimum of 
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three replicate assays was performed. The inter- and intra-assay variations (n >10) were 
determined as well. 
Inhibition of MBL activation in the functional assay by competing carbohydrates. 
This was done by preincubating test serum samples with mannose, N-acetyl-D-
glucosamine (GlcNAc), or galactose at 37˚C for 30 min, starting with a concentration of 
2.5 mg carbohydrate per well. A checkerboard titration was done in the following 
manner: HPS was diluted in all the horizontal rows of the microtiter plate, and dilutions 
(1/3) of the carbohydrates were tested (833, 278, 92.6, 30.9, 10.3, and 3.4 µg/well), 
in the vertical rows. 
The effect of C1-inhibitor in the functional assay. C1 esterase inhibitor (C1-INH) 
with a concentration of 1 mg/ml was added to the functional assay. The highest 
concentration tested was 350 µg/ml, which is the physiological concentration of C1-
INH. Final concentrations of 175 and 87.5 µg/ml C1-INH were also tested. Per well, 
350 µg C1-INH or a dilution thereof was mixed with serial dilutions of human pooled 
serum. The mixture was allowed to incubate at 37˚C for 30 min before the addition of 
yeast cells, MBL-deficient serum and chicken erythrocytes. Putative direct hemolysis by 
C1-INH was ruled out by adding C1-INH to erythrocytes and MBL-deficient serum 
only. 
Anti-MBL monoclonal antibody (MoAb) and purified human MBL. The 
commercially available anti-MBL IgG1 antibody clone 131-1 (1 mg/ml; lot 
01044PA01) was obtained from the Statens Serum Institute in Copenhagen, Denmark. 
Human recombinant MBL, which was a kind gift from Dr. R.A.B. Ezekowitz (Boston, MA, 
USA), was more than 95 % pure. 
MBL-specific competitive enzyme-linked immunoassay (ELISA). MBL levels in human 
sera were estimated using a protein-specific competitive ELISA. This was executed as 
follows: ELISA plates were first coated with 1.5 µg/ml recMBL in phosphate-buffered 
saline (PBS), and blocked with 4% skim milk in PBS. Then, mixtures were prepared 
consisting of 1/5,000-diluted anti-MBL monoclonal antibody in PBS and equal volumes 
of serial 10–0.5 dilutions of test samples, which were allowed to incubate for 1 h at room 
temperature. After incubation, the amounts of bound antibody were tested by 1/6,000-
diluted peroxidase-labeled anti-mouse IgG antibody in PBS (Nordic, Tilburg, the 
Netherlands). Tetramethylbenzidine was used as the chromogenic substrate. After each 
incubation step, the wells were thoroughly washed. Two sera with MBL levels of 0.396 
µg/ml and 1.248 µg/ml (a kind donation of Dr. P. Garred, Copenhagen, Denmark) were 
used as intermediate- and high-level MBL references, respectively.  
Human anti-mannan antibodies. A serum sample from an MBL-deficient subject (ELISA 
titer: 0.06 µg/ml), with a high anti-mannan antibody titer (IgG: 8.7 mg/l; IgM 5.6 mg/l; 
A.G.S.), was tested for functional MBL in order to study the influence of classical pathway 
activation on the outcome of the assay.  
Statistical methods. The Pearson correlation coefficient was calculated and used to 
analyze data generated by both the functional MBL test and the competitive MBL ELISA 
that was applied to the sera of the 121 blood donors. Inter- and intra-assay coefficients 
of variation were estimated from 10 measurements of HPS using the equation: (s : x) x 
100%, where s is the sample standard deviation and x the sample mean. 
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RESULTS 
 
    The known MBL-deficient donor serum was tested in the functional assay against the 
human serum pool, which had an established antigenic MBL level of 1.67 µg/ml. The 
level of antigenic MBL in our reagent serum was 0.206 µg/ml. Several reagent serum 
concentrations were tested initially in the functional assay, but a final concentration of 
1% reagent serum proved to yield the best results with the least contribution (equal to an 
MBL concentration of 0.02 µg per ml) of the alternative pathway, measured with EGTA-
VB instead of VBS++ (Fig. 1). Based on the MBL-deficient serum from the regular donor, a 
Z value of 0.200 proved to best estimate functional MBL titers (Fig. 2). The intra-assay 
variation was 5.6% and the inter-assay variation was 5.2%. 
 
 
Fig. 1. The effects of 1% (1a) and 1.7% MBL-deficient serum (1b), as the reagent in the functional MBL 
assay, on the apparent functional activities of human pooled serum (HPS), expressed in arbitrary units 
(AU) per ml. Note that the alternative pathway activity of 1.7% MBL-deficient serum (measured in EGTA-VB) 
exceeds the apparent MBL activity (measured in VBS++). Vertical bars indicate standard errors of the mean. 
 
 
Fig. 2. Functional MBL levels are read at a Z value of 0.2. 
 
Sera from 121 donors to a blood bank were tested with both a competitive ELISA and 
the functional assay. A highly significant (P <0.0001) positive correlation (r = 0.869) 
was found between the MBL ELISA results and the functional MBL levels, as shown in 
Figure 3. The intercept of the line is at about 0.2 µg/ml equivalent and not at zero. 
 51
Fig. 3. Comparison of functional MBL levels obtained with the functional assay (shown on the y-axis), 
with data obtained with a competitive ELISA (shown on the x-axis). Sera tested were from donors to a 
blood bank (n=121). 
 
 
    The MBL-deficient serum with high anti-mannan antibody titers scored 0.06 µg 
MBL/ml when tested with ELISA, and 0.12 µg-equivalent MBL/ml when tested with our 
functional assay. We also studied the inhibition of lectin pathway activation by the 
carbohydrates GlcNAc, D(+)mannose, and D(+)galactose using our functional assay. 
GlcNAc (Fig. 4a) and mannose (not shown here) fully blocked MBL-mediated hemolysis, 
while galactose did not (Fig. 4b).  
 
Fig. 4. Saccharide-mediated inhibition of MBL activity by the saccharide N-acetyl-D-glucosamine 
(GlcNAc) (4a), but not by galactose (4b). 
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When the MASP-1-and MASP-2-binding C1-inhibitor was added to the MBL functional 
assay, hemolysis was blocked in a concentration-dependent way (Fig. 5). 
          
Fig. 5.  The influence of C1-esterase inhibitor (C1-INH) on MBL serum levels in the functional assay. 
C1-INH is a known inhibitor of complement activation. Human pooled serum (MBL: 1.67 µg/ml) without 
C1- INH is used as a control (C). 
 
 
DISCUSSION 
 
    This paper describes a new hemolytic assay for estimating the functional activity of 
mannose-binding lectin (MBL), the leading component of the lectin complement 
pathway. Baker’s yeast cells were chosen as MBL-activating particles for this assay, 
because their cell wall is rich in mannan and because Saccharomyces cerevisiae was the 
first reported microorganism to be associated with MBL [24]. Before MBL was recognized 
as a complement component, defective yeast opsonization had already been described 
in 25% of children with frequent unexplained infections [25]. This defective yeast 
opsonization had also been noted in the sera from children with an increased incidence of 
infection or atopy [26]. Defective yeast opsonization was functionally measured using 
opsonized baker’s yeast as the substrate for PMN-dependent phagocytosis [25, 27], by 
studying neutrophil iodination response [28] and by measuring chemoluminescence 
emitted by PMNs upon incubation with yeast cells opsonized with normal or deficient 
sera [27]. Tests involving PMN function, however, suffer from the disadvantage that their 
results may differ from PMN donor to donor due to the many Fc-receptor polymorphisms 
that occur in the population.  
    Although another assay has been described for the measurement of MBL-initiated 
hemolysis based on the lysis of mannan-coated erythrocytes [18], the test we describe 
here seems to be less complex and less laborious, while the accuracy is acceptable (about 
5% inter-and intraday variability). The test we present here appears to be very useful for 
measuring functional MBL, not only in the normal serum-level range, but also in case of 
deficiencies. Other, less sensitive assays, e.g. those based on nephelometry, often lack 
linearity at the low-level range. A strange, but reproducible, observation was that the 
functional assay does not detect MBL levels below 0.20 µg MBL equivalent per ml. This 
intrinsic property of the functional assay is not easy to explain, unless we suppose that the 
chains encoded by variant MBL alleles have some residual functional activity. 
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    As far as the MBL activator in this functional assay is concerned, all yeasts are efficient 
activators of the alternative complement pathway, but the advantage of S. cerevisiae is 
that it lacks pathogenicity. With regard to a possible contribution to the eventual MBL 
titer of the alternative pathway constituents in the MBL-reagent serum, we found that this 
is not more than 5%, at least when using 1% MBL-deficient serum, which we consider to 
be negligible. 
    The apparently low MBL activity found in MBL-deficient serum with high anti-mannan 
immunoglobulin levels indicate that classical pathway activation by anti-mannan 
antibodies is not likely to contribute to major false-positive MBL results. This is in line with 
findings by Super et al. [29] who did not observe any correlation between the levels of 
IgG1, IgG3, or IgM anti-mannan antibodies and level of C4 or C3bi binding. This 
allowed us to conclude that, in an experimental system using low serum concentrations, 
MBL cleaves complement component C4 in an antibody-independent manner. In 
samples with low C4 serum levels, which theoretically is possible in homozygous C4A or 
C4B deficiency, MBL activation still leads to hemolysis in the assay due to MASP-1 
induced C3 cleavage. The latter ‘bypass mechanism’ will not be found in a C4-binding 
assay as described previously [30]. 
    The two carbohydrates with equatorial 3- and 4-OH groups (mannose and GlcNAc) 
inhibited MBL-dependent bystander lysis in a dose-dependent manner. In contrast, 
galactose, which does not fulfill these spatial demands, showed less inhibition of 
functional MBL, thereby confirming earlier findings by Holmskov et al. [31]. These 
researchers demonstrated the saccharide selectivity of collectins using a solid-phase 
assay, in which human MBL was best inhibited by GlcNAc, less by mannose, and not at 
all by galactose.  
    C1 esterase inhibitor (C1-INH), which is a known inhibitor of complement activation 
via the classical pathway subcomponents C1r and C1s, has been recognized as an 
inhibitor of the lectin pathway through binding to MASP-1 and MASP-2 [32]. In our 
functional assay, profound inhibition was seen at levels of 350 and 175 µg per ml, which 
confirms the finding by Matsushita et al. (2000) that C1-INH is a potent inhibitor of 
MBL-MASPs in a hemolytic system. Results obtained with the putative lectin pathway 
inhibitors α2-macroglobulin [33-35] and aprotinin were inconclusive and therefore not 
described in this paper.  
    Recently, using this functional MBL assay, we tested more than 750 serum samples 
from young children suffering from unexplained, repeated episodes of otitis media due to 
pneumococcal infection. Our results showed a very high incidence of MBL deficiency in 
these children as measured by the functional assay. The lower cut-off value used (0.2 µg 
MBL equivalents per ml) was based on an epidemiological study in the Dutch population 
(submitted for publication; very low serum MBL: < 0.2 µg MBL equivalents/ml; low serum 
MBL: 0.2 – 0.42 µg MBL equivalents/ml). The incidence of functional MBL deficiency 
ranged from 24.6 to 35.3 percent, depending on the age group tested, versus 4.9 
percent in the control group (unpublished results). Based on these and the results 
mentioned above, this novel functional MBL assay could be very useful for large-scale 
testing in the medical immunology laboratory. 
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ABSTRACT  
 
Mannose-binding lectin (MBL) is a serum complement factor playing a dominant role in 
first-line defense. When MBL binds to specific sugar moieties on microorganisms, the 
lectin complement pathway (LCP) is activated. Changes in the mbl gene and promotor 
may result in MBL with less activity, predisposing the individual to recurrent infections. 
Using a functional MBL assay, we investigated at what concentration different microbes 
activated MBL. Less than 1 CFU of Neisseria meningitidis group B and C still activated 
MBL, which may be ascribed to filterable blebs. Nocardia farcinica and Legionella 
pneumophila activated MBL well, which raises new questions about host susceptibility. In 
contrast to other research, Pseudomonas aeruginosa activated the LCP potently. 
 
 
INTRODUCTION 
 
    Mannose-binding lectin (MBL) is an ancient complement protein discovered only a 
few decades ago [1,2]. Being the leading protein of the lectin complement pathway 
(LCP), it belongs to the family of calcium-dependent collagenous lectins (collectins) [3]. 
This C1q-like molecule has three identical sugar-binding domains with specificity for 
mannose, N-acetyl-D-glucosamine (GlcNAc), and fucose, but not for antibodies. When 
one or more of these sugars are present on a microbial surface, binding and subsequent 
activation of MBL will take place, which indirectly leads to C3b and C3bi deposition on 
the microbial surface as well.  
    The LCP comprises MBL and its associated serine proteases, and complement 
components C4, C2, and C3. The latter three components are shared with the 
phylogenetically younger classical complement pathway, which becomes activated when 
microorganisms bind immunoglobulins. MBL activation results in direct microbial 
opsonization and/or microbial lysis via membrane attack complexes [4], a property that 
makes the lectin complement pathway part of the innate immune system.  
    Certain microorganisms appear to be ideal substrates for MBL binding and subsequent 
lectin pathway activation. E.g, the fungal cell wall is relatively rich in mannan 
(polymerized mannose) [5], the mycobacterial cell wall rich in lipoarabinomannan 
(LAM) [6], and GlcNAc constitutes an important building stone of peptidoglycan of 
bacterial cell walls [7]. Bacterial capsules also contain a variety of polysaccharides 
including GlcNAc, mannose, fucose, and derivatives thereof, which suggests that certain 
capsular types may activate the lectin pathway as well. In fact, MBL binding to various 
bacterial, fungal, viral, and parasitic agents has been demonstrated by means of flow 
cytometry [8,9], radio-immunoassay [10,11], ELISA [11,12,13], or electron microscopy 
[14]. MBL binding has been tested functionally using a C4b-deposition assay [15,16]. 
However, discrepancies in MBL binding and activation by microbes may be found, 
depending on the method used.   
   Recently, we devised a novel, hemolytic assay for the estimation of functional MBL, 
based on the phenomena of Saccharomyces cerevisiae-induced MBL activation and 
subsequent bystander lysis of chicken erythrocytes [17]. MBL was the rate-limiting factor 
in that assay, making the test highly specific for MBL. In the present study, we used the 
same assay to compare MBL activation by different microorganisms. 
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MATERIALS AND METHODS 
 
Human pooled serum. Blood collected from healthy workers of our laboratory was 
allowed to clot for 60 min before centrifugation (1,500 x g) at room temperature for 10 
min. Sera were then pooled (human pooled serum; HPS), and stored in100-µl aliquots at 
-70ºC until further use.  
MBL-deficient serum. Serum from an MBL-deficient subject was used as MBL-reagent 
serum. This serum was also stored in 100 µl aliquots at -70ºC.  
Microbial strains. The microbial strains tested in the functional MBL assay comprised a 
selection of defined strains, including those from the American Type Culture Collection 
(ATCC) and the British National Culture Type Collection (NCTC). The Gram-positive 
bacterial strains tested included: Staphylococcus aureus Cowan I, Micrococcus 
lysodeikticus, Enterococcus faecalis ATCC 29212, unencapsulated Streptococcus 
pneumoniae strain Rx1 (kindly provided by Dr. Larry McDaniel, Jackson, MI, USA), and 
group-A beta-hemolytic Streptococcus strain NY-5, which is a strong exotoxin SPE-A1 
producer [18]. 
     The Gram-negative bacterial strains included were: Legionella pneumophila NCTC 
11233, Helicobacter pylori (patient isolate), Escherichia coli ATCC 25922, Salmonella 
typhimurium strains M206 and the M206 Re mutant (with LPS lacking the O-antigenic 
side chain, composed only of keto-deoxyoctonic acid and lipid A) [19], and Yersinia 
enterocolitica serotype O:3. Four Neisseria gonorrhoeae strains differing in piliation and 
opacity protein (F62, N300 (piliated, Opa-negative), N303 (piliated, Opa50), and 
N392 (piliated, Opa30)) [20,21] were a kind gift from Dr. M. Dehio, Tübingen, 
Germany), and Neisseria meningitidis group B and C (patient isolates) were also included 
in our assay for MBL activation.  
    Non-fermenting Gram-negative strains tested were: Burkholderia cepacia ATCC 
25417, Pseudomonas aeruginosa ATCC 27853, P. aeruginosa ATCC 10145, and a 
mucoid P. aeruginosa isolate cultured directly from the sputum of a cystic fibrosis patient. 
    The actinomycete Nocardia farcinia was a clinical isolate. The National Institute for 
the Environment and Public Health (RIVM, Bilthoven, the Netherlands) provided the 
Mycobacterium bovis BCG strain. Candida albicans ATCC 14053 was obtained 
commercially. Baker’s yeast (Saccharomyces cerevisiae) was used as the reference 
organism at a concentration of 6 x 106 yeast cells ml-1.  
Microbial cultures. Strains were cultured according to standard procedures [22]. 
Legionella pneumophila was cultured on BCYE agar (Oxoid, Basingstoke, UK), 
gonococci on GC agar (Becton Dickinson, Cockeysville, MD, USA), both 
meningococcal strains on Columbia blood agar (Oxoid), Helicobacter pylori on Belo 
Horizonte medium (Oxoid), Burkholderia cepacia on Burkholderia cepacia agar (Oxoid), 
the yeasts Candida albicans and Saccharomyces cerevisiae on Sabouraud agar (Merck, 
Darmstadt, Germany), and Mycobacterium bovis BCG in Dubos liquid medium (Difco, 
Le Pont du Claix, France) supplemented with glycerin (Merck) and bovine albumin 
(Sigma, Zwijndrecht, the Netherlands). All other bacterial strains were cultured on 
Columbia blood agar.  
    For use in the functional assay, the microorganisms were suspended in veronal-
buffered saline with 0.15 mM Ca2+ and 0.5 mM Mg2+ (VBS++), until an absorbance value 
of 1.0 at 660 nm was reached. The microbial suspensions were serially diluted (1/2 up to 
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1/6,4 x 107). In order to study activation by subcellular products of meningococci, 
meningococcal suspensions were filtered through a 0.22 µm syringe filter (Gelman 
Sciences, Ann Arbor, MI, USA). Bacterial concentrations at OD 1.0 varied from 1.5 x 
108 colony-forming units (CFU) per ml for Neisseria species to 1.1 x 109 for B. cepacia. 
Microorganisms were enumerated microscopically by the Thoma slide counting chamber 
method (W. Schreck, Hofheim, Germany). 
Functional microtiter assay for MBL activation by microorganisms. The functional 
MBL test used to study MBL activation by microorganisms was derived from a recently 
developed assay based on Saccharomyces cerevisiae-induced bystander C5b6-
mediated hemolysis of chicken erythrocytes (ChE) [17]. In that assay, serum to be tested 
for functional MBL was serially diluted (10–0.5). A fixed amount of MBL-activating baker’s 
yeast cells (3.0 x 105 cells/well), MBL-deficient serum (1.5 µl/well) providing all 
complement components except MBL, and target cells (1x 107 ChE/well) was added. 
The conditions were chosen in such a way that MBL was the rate-limiting factor in that 
assay. 
    In the present assay, MBL-activating S. cerevisiae was substituted by other 
microorganisms. The different microbial concentrations were added in a 50-µl volume 
per well. A checkerboard titration was done as follows: HPS (as the source of MBL) was 
serially (10-0.5) diluted, starting with a dilution of 10% HPS in VBS++ per well (final 
concentration 3.3% HPS) in the horizontal lines of the microtiter plate, while the serially 
diluted microorganisms were added to the vertical rows. Per microtiter plate, a 5-ml 
mixture was made containing 150 µl MBL-deficient serum and 109 ChE in VBS++. A 50-
µl sample was taken from this mixture and added to each test well. Then, the plate was 
incubated at 37ºC for 1 h, and spun for 10 min in a microtiter centrifuge. Thereafter, 
50-µl samples of each supernatant were transferred to a flat-bottom plate containing 
200 µl water per well. Hemoglobin release was measured in an ELISA reader operating 
at a wavelength of 405 nm. 
    Percentages of hemolysis were calculated using controls for 100% (water-lysed) and 
0% (buffer incubated) hemolysis. The percentages were then transformed according to 
the equation published by Borsos and Rapp [23]:  
 
                               Z = -ln  (1 – fraction of erythrocytes lysed)  
 
in which Z is the mean number of active sites per chicken erythrocyte. Human pooled 
serum (HPS) in EGTA-VB (8 mM ethylene glycol bis-(β-aminoethyl ether)-N,N,N’,N’-
tetraacetic acid with 2.5 mM Mg2+) was used to test alternative pathway activation by 
the various microbes. Direct hemolysis of the erythrocytes by microbial products was 
excluded by incubating microorganisms and erythrocytes together with MBL-deficient 
serum only. Microbial MBL activation was related to the MBL activity of 3 x 105 S. 
cerevisiae cells/well in a 50-µl volume, added to a HPS dilution series in the same 
microtiter plate as the microbe tested. The microbial concentration giving rise to a Z 
value of 0.6 (calculated by: Z microorganism / Z S. cerevisiae = 0.6) was used as a means to rank the 
microorganisms based on their MBL-activating capacities. All experiments were 
repeated at least twice. 
Specificity of microbial MBL activation. To test the specificity of microbe-induced 
MBL activation, experiments were also executed in the presence of serial (1/3) dilutions 
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of either D(+)-mannose (Sigma) or N-acetyl-D-glucosamine (Serva, Heidelberg, 
Germany). The highest saccharide concentration tested was 2.5 mg per well. MBL-
containing human pooled serum (20%; 25 µl) samples were preincubated with the 
saccharide (25 µl) at 37ºC for 30 min. After incubation of the saccharides with HPS, 
microbial cells were added. Sugar-inhibitable hemolysis was considered MBL-mediated.  
 
 
RESULTS 
 
    A functional MBL assay was used to compare MBL activation by different 
microorganisms. In the test, microbial numbers as well as the MBL concentration was 
varied. Curves obtained were mostly straight parallel lines, showing less hemolysis with 
decreasing numbers of bacteria. Incidentally, optimum curves were obtained. By 
determining the intersection of the straight lines with the horizontal line Z = 0.6, the 
number of microorganisms activating MBL in the assay could be compared (Table 1).  
 
 
Table 1. Ranking of microorganisms according to their MBL-activating capacities. Z value stands for the 
amount of hemolysis in the functional assay, showing the active sites per erythrocyte. CFU: colony-
forming units. 
 
Microbial strain Concentration at Z = 0.6 (CFU) 
Neisseria meningitidis group B 1 
Neisseria meningitidis group C 1 
Nocardia farcinica 5 
Neisseria gonorrhoeae F62 50 
Neisseria gonorrhoeae N300 50 
Neisseria gonorrhoeae N303 50 
Neisseria gonorrhoeae N392 50 
Salmonella typhimurium M206  75 
Salmonella typhimurium M206 Re mutant 300 
Mycobacterium bovis BCG 400 
Saccharomyces cerevisiae 1350 
Pseudomonas aeruginosa ATCC 27853 5000 
Pseudomonas aeruginosa ATCC 10145 5000 
Pseudomonas aeruginosa mucoid (CF) 5000 
Candida albicans ATCC 14053 3 x 105  
Legionella pneumophila NCTC 11233 5 x 106   
Yersinia enterocolitica 3 x 107 
Micrococcus lysodeikticus 3 x 107 
Staphylococcus aureus Cowan I 3 x 108 
Helicobacter pylori 3 x 108 
Escherichia coli ATCC 29522 3 x 108 
Enterococcus faecalis no activation at all 
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    In order of decreasing MBL-activating abilities, the following microbes were ranked: 
Neisseria meningitidis groups B and C, Nocardia farcinica, the four gonococcal strains, 
(showing equal MBL-activating capacities irrespective of pili or opacity protein), 
Salmonella typhimurium, the Re mutant of S. typhimurium (lacking the O-antigenic side 
chain, theoretically having less MBL-activating sites), Mycobacterium bovis BCG, 
mucoid and non-mucoid Pseudomonas aeruginosa (showing no difference on outcome 
between mucoid and nonmucoid strains), Candida albicans, Legionella pneumophila, 
Yersinia enterocolitica, Micrococcus lysodeikticus, Staphylococcus aureus Cowan I, 
Escherichia coli, and Helicobacter pylori. The Enterococcus faecalis strain did not 
activate MBL at all.  
    The competitive, inhibitory effect of MBL-specific saccharides on lectin pathway 
activation is shown for the reference organism S. cerevisiae and for the unencapsulated 
Gram-positive bacterium Micrococcus lysodeikticus. S. cerevisiae-induced MBL 
activation could be counteracted by adding to the sera to be tested 2.5 mg/well or 1/3 
dilutions of this suspension of D(+)-mannose, the carbohydrate substrate with the greatest 
affinity for MBL (Fig. 1a). N-acetyl-D-glucosamine competed with M. lysodeikticus for 
MBL binding in the same manner, as is shown in Fig. 1b. MBL-activation by all other 
microbes tested could be inhibited by the saccharides too. 
    The finding that Neisseria meningitidis groups B and C still caused MBL-mediated 
hemolysis despite low bacterial concentrations demanded additional experimental 
information. After passing the meningococcal suspensions through a microbial filter, no 
differences were seen between the amount of MBL-induced hemolysis caused by the 
unfiltered suspension and the filtered one (not shown).  
    Some microbial strains produced hemolysins that lysed the chicken erythrocytes. 
Therefore, these strains could not be evaluated in the functional MBL assay. This was true 
for group A β-hemolytic streptococcus strain NY-5, Burkholderia cepacia ATCC 
25417, and the heat-killed, unencapsulated Streptococcus pneumoniae strains Rx1.  
 
 
Fig. 1. Competition of carbohydrates and bacteria for MBL binding. (1a) Mannose inhibition of 
Saccharomyces cerevisiae-induced MBL activation. (1b) N-acetyl-D-glucosamine (GlcNAc) inhibition 
of Micrococcus lysodeikticus-induced MBL activation. 
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DISCUSSION 
 
    Many experiments regarding complement activation by different microorganisms were 
carried out either before the definite recognition of the alternative pathway (around 
1980) [24], or when the lectin pathway was yet to be discovered (before 1989). This 
necessitates reevaluation of the capacities of different microorganisms to activate the 
three complement pathways. The ancient lectin pathway, activation of which was the 
subject of this study, leads to antibody-independent microbial coating with C3b, and 
ingestion in cells of the monocyte phagocyte lineage or, in case of e.g. Neisseriae, in 
terminal complement pathway (TCC)-mediated microbial lysis. As multiple Fc-receptor 
polymorphisms of polymorph nuclear (PMN) leukocytes severely complicate opsonic 
studies, the focus of this paper is restricted to functional activation of MBL by 
microorganisms.  
    For the purpose stated above, we modified a recently developed, functional MBL 
assay, based on the principle of yeast-induced, C5b-6-mediated bystander hemolysis of 
chicken erythrocytes [17]. The hemolytic assay, specific for MBL by using MBL-deficient 
reagent serum, combines Saccharomyces cerevisiae-induced MBL pathway activation 
with bystander hemolysis of chicken erythrocytes. The assay is easier to perform than 
complement fixation assays, and very reproducible. As shown previously, the influence of 
classical complement pathway activation is minimized in hemolytic assays when using 
diluted serum of less than 5 percent [25] . Competition of MBL with carbohydrates is a 
measure of the remaining complement activity induced by the HPS used (Fig. 1). The 
influence of antibodies on classical pathway activation in this MBL assay was studied with 
S. cerevisiae, using serum from an MBL-deficient subject; the effect of this IgG- and IgM-
containing serum was negligible.  
    By substitution of baker’s yeast, the MBL-activating capacity of microbes other could 
be evaluated. The most striking finding was that, depending on the microbe tested, either 
straight lines or optimum curves were obtained (X-axis: number of microorganisms; Y-
axis: Z value, or number of active sites per cell). The ‘optimum curve’ phenomenon can 
be explained by microbe-induced depletion of early complement components C2 and 
C4 upon testing higher microbial concentrations, resulting in less hemolysis than 
expected.  
    Several of our results differ dramatically from those found by others for several 
microorganisms tested. For example, very weak or absent MBL binding by Pseudomonas 
aeruginosa was found by other researchers [15,26], and functional MBL activation by P. 
aeruginosa strains (n = 7) could not be detected in a functional C4-binding assay [15]. P. 
aeruginosa belongs to the non-fermenting group of Gram-negative bacteria involved in 
severe pulmonary infections in cystic fibrosis (CF) patients, resulting in a shortened life-
span in those patients carrying variant MBL alleles [27]. MBL activation as shown in our 
assay provides a better explanation for the severe infections in MBL-deficient CF 
patients. 
    Extremely low concentrations (≤ 1 CFU) of group B and C meningococci still activated 
MBL to a Z value of 0.6 in the functional assay. A new finding is that, even after filtration 
of the bacterial suspensions, unambiguous MBL activation was found, pointing towards a 
soluble MBL-activating factor. A candidate factor may be the ‘blebs’, vesicles formed by 
parts of the meningococcal outer membrane. Blebs, consisting partly of LPS, are secreted 
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in serum and cerebrospinal fluid within seconds in vitro as well as in vivo [28]. Although 
previous experiments showed that MBL can bind to sialylated meningococcal LPS 
[29,30], and to opacity and porin B proteins (M.M. Estabrook, D.J. Jack, N.J. Klein, and 
G.A. Garvis, Abstr. 5th Internat. Workshop on C1, and collectins, abstr.II-3, 2001), our 
findings show the importance of a soluble, filterable factor in meningococcal pathology, 
which raises new questions, and may explain the increased susceptibility of MBL-deficient 
persons to meningococcal disease [31]. 
    Gonococcal pili and opacity protein variations do not contribute to differences in the 
lectin pathway-activating capacity. Also, the ability of gonococci to activate MBL 
functionally is less pronounced when compared to meningococci. 
    S. cerevisiae, the first reported microorganism associated with MBL [1], is a yeast of 
low pathogenicity. Its potent MBL-activating capacity can be related to the high 
polysaccharide content of the cell wall, which consists mainly polymers of N-
acetylglucosamine (chitin), glucose (β-glucan), and mannose (mannan) [5]. The cell wall 
of C. albicans resembles that of S. cerevisiae, but the two yeast species differ in 
pathogenicity [5]. Surprisingly, more Candida albicans cells were needed to achieve the 
same amount of hemolysis when compared to S. cerevisiae. Whereas clinical disease with 
S. cerevisiae is rare, Candida species cause mucosal and systemic disease in both normal 
and immunocompromized patients. Immunity to Candida infections is complement-
related [32], but also dependent on the quantity and quality of peripheral phagocytes 
and on T-cell function. 
    Since MBL binding leads to opsonization and internalization in monocytes and 
monocyte-derived macrophages, it can be theorized that normal serum MBL levels 
predispose to more severe disease with intracellular pathogens, which survive and 
replicate in monocytes and macrophages. This theory has been confirmed in patient 
studies for tuberculosis in HIV-negative individuals [33,34,35] and for Ethiopeans 
suffering from leprosy, which is caused by Mycobacterium leprae [36]. Also, a direct 
correlation has been found between high MBL levels and the development of invasive 
(visceral) leishmaniasis, which is caused by the intracellular protozoa Leishmania chagasi 
[37]. As expected, very low concentrations of the intracellular microorganism 
Mycobacterium bovis BCG activated MBL in our assay. This can be explained by vivid 
MBL binding to the mycobacterial cell wall components peptidoglycan and 
lipoarabinomannan (LAM). The role of MBL in e.g. M. avium-intracellulare infections in 
HIV-patients, demands further research. 
    The intracellular pathogen Legionella pneumophila activates the lectin pathway, 
which may represent a quick means of transport of the bacterium into pulmonary 
macrophages after inhalation by the host. In the macrophages, bacterial replication takes 
place within 2-4 hours [38], which may result in severe pneumonia. MBL deficiency may 
protect against severe legionellosis, which is currently under investigation.  
    Our study confirms the strong MBL-activating ability of the intracellular Salmonella 
species. The decreased MBL-activating capacity in the functional assay of the Re mutant 
can be explained by the shorter LPS side chain, composed only of lipid A and keto-
desoxy-octonic acid.  Other authors confirmed that MBL binds avidly to Salmonella 
typhimurium core LPS structures, and that this type of binding is abrogated by the 
addition of O-antigen [39].  
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    Until now, no study has looked at the role of innate complement proteins and the 
pathogen Nocardia farcinica, which causes pulmonary infections beside brain abscesses 
in patients with dysfunctional cellular immunity. One would expect that nocardial 
infections would be more common, knowing that many people carry variant MBL alleles. 
However, this microorganism grows slowly and is usually killed by macrophages and T-
lymphocytes [40]. 
    The pathogen Yersinia enterocolitica activates MBL in our assay, a finding demanding 
further research. After ingestion of meat and refrigerated food, this pathogen causes 
gastroenteritis and, rarely, reactive arthritis.  The role of MBL in Helicobacter pylori-
associated gastritis, gastric ulceration and lymphoma (MALT-type B-cell) also remains to 
be elucidated. Recent research showed that H. pylori activated the classical pathway in 
the absence of specific antibodies, at least via LPS [41], but specific lectin pathway was 
not studied. However, as H. pylori activated MBL in the functional assay, it is more likely 
that the lectin pathway is the major complement pathway involved in opsonization of the 
bacterium. 
    Testing the MBL-activating capacities of microorganisms in fixed circumstances may 
not be representative for what happens in the host, and it is more likely that our 
functional assay approaches the more complex in vivo situation. Therefore, ranking of 
microorganisms in terms of MBL activation can give a different impression from the 
ranking of microbes in terms of MBL-binding. 
    Several bacteria show α- or β-hemolytic activity when cultured on sheep blood agar, 
and this quality makes these strains unsuitable for testing in the functional MBL assay 
using chicken erythrocytes. For instance, Streptococcus pyogenes contains powerful 
hemolysins. The same holds true for Burkholderia cepacia, and the unencapsulated 
Streptococcus pneumoniae strain.  
    In conclusion, our functional MBL assay can be used to evaluate MBL binding and 
activation by most microbes, providing new insight in the double role of MBL in genetic 
susceptibility to microbial diseases. The present study shows that extremely low 
concentrations of meningococci lead to profound MBL activation, as do filterable 
meningococcal products. Contradictory to other in vitro studies, Pseudomonas 
aeruginosa does activate MBL, providing experimental evidence for the clinical 
outcomes in MBL-deficient CF patients. New insight was gained in the activation of MBL 
by Legionella pneumophila, Nocardia farcinica and Helicobacter pylori, raising exiting 
new questions as to the role of this ancient protein in (intracellular) infection. 
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ABSTRACT 
 
Deficiency of mannose-binding lectin (MBL), one of the most important proteins of 
innate immunity, alters susceptibility to infection. Using a hemolytic assay, we 
investigated functional MBL serum levels in a cohort of pneumonia patients from a 
legionellosis outbreak in the Netherlands in 1999 (n = 124), and compared these 
to 447 controls. A significantly higher incidence of MBL deficiency (serum 
MBL<0.20 µg equivalents/ml; X=96.7; P<0.001) was found in the patients, 
whereas MBL deficiency in 59 asymptomatic, exposed individuals was comparable 
to the controls. We conclude that MBL deficiency is a novel risk factor for 
Legionella pneumophila pneumonia.  
 
 
     Legionella pneumophila is an intracellular gram-negative bacterium capable of 
surviving and replicating in cells of the human mononuclear phagocytic system. Infection 
may lead to an acute selflimiting flu-like illness called Pontiac fever, or to a severe 
pneumonia that has a calculated case fatality rate of 11-18 %. In 1999 in Bovenkarspel, 
the Netherlands, a large outbreak of pneumonia caused by L. pneumophila type 1 
occurred at a well-attended flower show. The outbreak included 188 patients, of who 
21 died. The source of the outbreak could be traced to a whirlpool in one of the 
exhibition halls. 1 
    Together with complement components C1 and C3b, mannose-binding lectin (MBL) 
belongs to the three initiators of complement activation, in case of MBL via the so-called 
lectin pathway (LP). LP activation begins when MBL binds to mannose, fucose or N-
acetylglucosamine moieties on microbes, thus leading to microbial opsonization, 
intracellular uptake and killing in monocytes and macrophages. 2 Three structural gene 
mutations determine serum MBL levels, further modulated by several promoter 
polymorphisms. 2,3 A calculated 32% of cases of disease with the gram-negative 
bacterium Neisseria meningitidis are associated with one or two MBL gene variants, with 
decreased serum MBL levels. 4 It is unknown whether MBL deficiency enhances 
susceptibility to infection with the gram-negative bacterium Legionella pneumophila. In 
this study, we investigated functional MBL levels in patients with L. pneumophila 
pneumonia in order to find out if there is a relation between severe clinical disease and 
deficiency of MBL. 
    All patients included in this study were visitors to the West-Frisian Flora Show (WF), 
which was held in February 1999 in Bovenkarspel. Case definitions were formulated by 
the Outbreak Management Team. A L. pneumophila ‘case’ was defined as a visitor to the 
WF with a clinically and radiographically confirmed pneumonia, and either a positive L. 
pneumophila type 1 culture or a positive urinary L. pneumophila type 1 antigen assay or 
a serologically confirmed rise in L. pneumophila antibody titer, without evidence of 
another microbial cause. A ‘probable case’ was defined as a visitor to the WF with a 
clinically and radiographically confirmed pneumonia, who did not meet the laboratory 
criteria for a confirmed case but in whom no other infectious agent could be identified. 1 
    The legionellosis group (n = 124) consisted of 92 cases and 32 probable cases. Their 
ages ranged from 20 to 86 years, with an arithmetic mean of 64.1 years (SD 10.4). The 
male to female ratio was 1.5 : 1. The control group consisted of 378 donors to the blood 
bank in Utrecht (age: 19 to 67 years), and 69 preoperative visitors to an orthopedic 
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outpatient department (age: 67 to 85 years). The mean age was 45.0 years (SD 17.2), 
and the male to female ratio 1.7 : 1. A third group consisted of 59 asymptomatic WF 
workers with positive L. pneumophila serology. Ages ranged from 15 to 76 years, with a 
mean of 45.7 years (SD 14.3), and a male to female ratio of 0.9 : 1. 
    Serum samples (stored at – 80 °C) from the Bovenkarspel legionellosis patients were 
tested them for functional MBL activity as described, 5 and the results were compared 
with the control group and the group of asymptomatic WF workers. In our laboratory, 
decreased functional MBL levels have been defined as levels below 0.42 µg per ml, and 
MBL deficiency as levels below 0.20 µg/ml. 5 
    Functional MBL titers in 640 samples tested ranged from < 0.13 to 6.04 µg 
equivalents per ml. Statistical analysis was done using a 3 × 2 χ2 test. As shown in the 
table, a significantly higher incidence of MBL deficiency (MBL < 0.20 µg equivalents 
per ml) was found in the patients as compared to the population controls (X [3x2 table] = 
96.7; P < 0.001). One WF worker (1.7 %) was found to be MBL deficient, while normal 
and decreased MBL levels were found in 79.7 % and 18.6 % of sera, respectively 
(table). 
 
 
Table. Functional serum mannose-binding lectin (MBL) levels in 124 cases of proven and probable 
legionellosis related to the Bovenkarspel outbreak in 1999. A group of 378 donors to a blood bank and 
69 preoperative visitors to an orthopedic outpatient department were used as controls. A group of 59 
asymptomatic workers with positive L. pneumophila serology was also included.  
 
Individuals           Functional MBL levels in µg eq/ml 
  -------------------------------------------------------------------------------------------------- 
                         Deficient (< 0.20)                 Low level (0.20-0.42)         Normal (> 0.42) 
 
Patients                  37a (29.8%)   20 (16.2%)    67 (54%) 
Controls   13   (2.9%)   45 (10.1%)  389 (87%) 
Exposed workers   1   (1.7%)   11 (18.6%)   47 (79.7%) 
 
a A significantly higher incidence of MBL deficiency was found in patients with Legionella pneumophila type 1 
pneumonia when compared to the controls (X [3x2 table] = 96.7; P << 0.001).  
 
 
    In the Netherlands, 13 % of the population shows decreased functional MBL levels.5 
Severe MBL deficiency has been found in 1.7 % to 3.1 % of the population, varying 
according to the population tested. Our results, both of the population controls and the WF 
workers, are in line with genotypic and phenotypic findings in the Caucasian population. 2,3 
MBL is evenly distributed among sexes, and in adults no age dependency is found. 
Although a weak acute phase reactant, in MBL-deficient individuals MBL levels cannot 
increase substantially even in the event of an infection, as was confirmed in our patient 
group. 
    Until now, the role of the MBL in the pathogenesis of legionellosis has not been 
described. Several non-genetic risk factors for legionellosis are known, including smoking, 
age, corticosteroid use, and chronic obstructive pulmonary disease. However, since there 
is no evidence that MBL phenotypes and genotypes influence the above named risk 
factors in our study, it was unnecessary to match patients and controls for additional risk 
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factors in the assessment of functional MBL levels in serum. Our hypothesis that MBL 
deficiency increases susceptibility to infection with Legionella pneumophila could be 
confirmed, although pathophysiological mechanisms that can explain our results remain 
to be elucidated.  
    In conclusion, in our case control study we found that extremely low MBL levels in 
serum are strongly associated with development of severe disease with Legionella 
pneumophila. This finding adds L. pneumophila to the list of microorganisms posing a 
threat to those individuals with MBL deficiency. 
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    It is almost beyond doubt that the main function of erythrocytes is to exchange and 
transport gases like oxygen and carbon dioxide to and from the lungs, respectively. In a 
similar manner, erythrocytes are able to transport toxic carbon monoxide, which shows 
that erythrocyte transport is not only used for beneficial purposes. In this discussion paper 
we will show that the above statements definitely are not the only truth about 
erythrocytic transport, and that at least part of erythrocyte function is devoted to the 
transport and/or elimination of  particles, including bacteria, (malaria) parasites, and 
lipoproteins. In the fast-growing field of immunology, it is beginning to be understood 
that erythrocytes are able to carry immune complexes to the liver, spleen and lungs [1]. 
This whole process seems to be governed by a single receptor (CR1 = C3b(i) receptor) 
that is present on primate erythrocytes but  lacking on erythrocytes of lower mammals. 
However, there is substantial evidence that in lower mammals like e.g. rodents, platelets 
rather than erythrocytes fulfill the CR1 carrier role as described in primates.  
 
 
EXAMPLES OF ERYTHROCYTE IMMUNOLOGY 
 
Example 1: Erythrocytes do not only bind gases. They are also able to bind and transport 
drugs like α-methyldopa and certain antimetabolites [2]. A teleological explanation for 
these phenomena could be that the binding of drugs to erythrocytes prevents the vessel 
wall from adverse reactions with the drug, which may protect the vessel wall from 
possible effects of type II hypersensitivity reactions (drug fever), or from drug-induced, 
direct toxicity. 
 
Example 2: Erythrocytes are also able to transport intact bacteria through the blood 
stream, probably to protect the vessel wall from unwanted inflammatory effects that may 
ultimately lead to premature vascular disease and, in the long run, even to 
atherosclerosis, or to target live bacteria to professional elimination sites including the 
spleen, liver and/or lungs. This erythrocyte-mediated bacterial transport and elimination 
mechanism has been described first by RA Nelson in 1953 who introduced the term 
‘immune adherence’ (Fig. 1) for this unique bacterial-erythrocyte interplay [3,4].  
 
 
Figure 1. Darkfield microscopy of Streptococcus 
pneumoniae immune adherence to an erythrocyte 
(R.A. Nelson, 1953). 
 
 
 
 
 
 
 
 
Later, as already pointed out, this mechanism  appeared to be mediated by a limited 
number (400 to 700) of erythrocyte-bound CR1 receptors on the erythrocyte. 
Although these numbers seem negligible, the large amounts of erythrocytes in circulation 
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ensure that this erythrocyte-mediated, immune elimination system is a very smart and 
effective one [4-7]. However, again thinking in teleological terms, the question remains 
which complement pathway opsonizes bacteria, making them ligands for CR1. It is known 
that the lectin and alternative complement activation pathways are, in evolution, the 
most ancient. Our first guess would be the lectin complement pathway, activation of 
which is mediated by mannose, N-acetylglucosamine, and fucose on gram-positive and 
gram-negative bacteria, yeast, mycobacteria, viruses, and parasites. This option seems 
logical, since the alternative complement pathway could easily amplify the signal 
initiated by the lectin pathway, while the alternative complement pathway is not a strong 
activation pathway per se. Later in evolution, the classical pathway could be the second 
best option, but only for people with a broad specter of specific antibodies or with an 
intact MBL pathway. However, in case of holes in their antibody repertoire and/or a 
diminished MBL function, individuals will probably need substitution therapy with 
parenteral IgG or MBL to sustain their failing immunity. 
 
Example 3: In the present proposal we would like to discuss how we would solve the 
question by which complement activation pathway the ‘immune adherence’ phenomenon 
is triggered. To answer this question, we propose to apply our three in-house, functional 
microtiter complement assays to measure in-vitro activation via the classical, the 
alternative, and the mannose-binding lectin pathway (shortly: the lectin pathway) [8,9]. 
To this end, we intend to use sera from different donors with deficiencies in MBL (e.g. the 
B/D variant), C1q, factor B, factor D, and IgG2. 
 
Example 4: In this short proposal, we also intend to highlight two recent findings related 
to the ‘immune adherence’ phenomenon and to quite similar erythrocyte-related 
phenomena, including the binding of gut-derived lipoproteins (chylomicrons) and very-
low-density lipoproteins (VLDL) to circulating erythrocytes. From these ex-vivo 
experiments, we learned that the erythrocytes do not only bind chylomicrons and VLDL 
in the circulation, but that they also transport and target the lipoproteins to sites of 
elimination, including the liver (the organ of the lipoprotein synthesis), the spleen and the 
lungs, in a manner similar to microorganisms (Fig. 2).  
 
Figure 2. Smears of 
erythrocytes obtained 
from a healthy MBL-
sufficient individual 3 
hours after a 12-hours 
fast (2a) and 3 h after an 
oral fat load (2b). Lipid 
particles were stained 
with Sudan black.                            
black. 
 
 
 
 
 
 
 a  b 
 76
    This finding strongly suggests that chylomicrons and VLDL both activate the 
complement system, and that these particles are opsonized and erythrocyte-bound. The 
question then arises via which pathway complement activation is achieved. So far, two 
pieces of evidence exist suggesting that this new phenomenon may be mediated by the 
lectin pathway (Fig. 3) [10]; first of all because the lipoproteins mentioned are heavily 
glycosylated with the sugars mannose, N-acetyglucosamine, and fucose [11], which all 
three happen to be strong binding sites for mannose-binding lectin and, secondly, that 
according to literature deficiency of mannose-binding lectin, which occurs quite 
frequently in our population (more than 12%; recent results), is associated with severe 
atherosclerosis [12].  
 
 
Figure 3. Lectin-dependent complement activation using a hemolytic assay as published by Kuipers et al. 
[9] using chylomicrons instead of Saccharomyces cerevisiae as activators of mannose-binding lectin 
(MBL). The figure on the left shows lipoprotein-induced MBL activation in human pooled serum (HPS) 
with MBL levels of 1.67 µg per ml versus MBL-deficient serum with an MBL level of 0.20 µg per ml. The 
right figure shows that lipoprotein-induced MBL activation can be inhibited by the addition of the 
saccharide mannose (2.5 mg/well). 
 
 
 
 
    Example 4: Colleagues working in the field of DNA vaccinology are often 
confronted with problems of diminished efficacy of their preparations [13], in our view 
due to early elimination that is likely to interfere with effectivity. We suggest here that 
also the poor efficacy of DNA vaccines may be a phenomenon that is mediated by 
MBL, which is most likely activated by the pentose-moieties in their constructs. 
 
    Purpose of the proposal: Purpose of our proposal is to confirm the importance of the 
lectin complement pathway in the protective, erythrocyte-mediated transport and 
elimination of chylomicrons, VLDL, DNA (constructs), and bacteria. 
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Abbreviations:  
AITD  : autoimmune thyroid disease 
RCCX  : genetic module coding for C4, steroid 21-hydroxylase CYP21,  
  Ser/Thr protein kinase RP, and tenascin. 
SLE   : systemic lupus erythematosus 
 
 
ABSTRACT    
 
Systemic lupus erythematosus (SLE) is an autoimmune disease affecting vessels and 
organs by precipitating immune complexes. Homo- and heterozygous deficiency of 
complement component C4A is the most common risk factor of human SLE from most 
races. We describe a female patient in her early teens with, as yet, partial SLE. Both 
parents, and 8 out of 9 uncles and aunts on the maternal side were partially C4A 
deficient. Surprisingly, in four of the relatives on the maternal side autoimmune thyroid 
disease had been diagnosed. The association between SLE and thyroid autoimmunity in 
patients and their families has been an ongoing subject of investigation. This paper 
focuses on C4 deficiency in this multicase family with autoimmune disease as described 
above. 
 
 
INTRODUCTION 
 
    Systemic lupus erythematosus (SLE) is a non-organ-specific autoimmune disease 
associated with deficiencies in the early components of the complement system such as 
mannose-binding lectin (MBL), C1, C2 and C4 [1-8]. Partial deficiency of the two 
isotypes of C4, C4A or C4B, is the most common inherited immune deficiency in 
humans. Together, C4A and C4B determine total serum C4 levels [9]. Serum C4 plays 
an important role in both the lectin and the classical pathway of complement activation, 
which both lead to coating of immune complexes and (microbial) particles with opsonic 
complement component C3b. Although C4A and C4B are highly related, their action is 
more or less polarized, C4B being more hemolytically and bactericidally active and 
engaged in the activation pathways, while C4A is more involved in immune complex 
clearance [10]. 
    In almost 35% of individuals from all over the world, the presence of C4A*Q0 or 
C4B*Q0 alleles has been demonstrated [6]. Deficiencies of MBL and C4A, but not of 
C4B, are linked to systemic autoimmunity. Complete deficiencies of both C4A and C4B, 
though rarely found, increases susceptibility to infections and, being an independent risk 
factor for SLE, almost invariably leads to SLE or lupus-like disease [3,11]. Identification of 
C4A and C4B allotypes are allowed by gross differences in electric charges of the 
variants, resulting in different electrophoretic migration patterns. In plasma from the 
patient’s parents the C4 haplotype A3B1 was found, which is the most frequent 
haplotype among Caucasians (frequency 0.466) [12]. Over 19 C4A and 22 C4B 
allotypes are recognized besides the null alleles C4A*Q0 and C4B*Q0.  
    Autoimmunity can cluster within families, thereby supporting the presence of genetic 
susceptibility. For example, 27% of SLE patients have a positive family history for 
autoimmune disease [13]. We describe a girl who was diagnosed with partial SLE in her 
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early teens. Her family history included other cases of SLE as well as thyroid 
autoimmunity. C4 protein allotyping was performed besides the study of C4 
polymorphisms, C4 gene dosage, and RCCX modules in all members of this multicase 
family with autoimmune diseases. 
 
CASE HISTORY 
 
    A 13-year old girl was seen by her general practitioner (GP) with the following 
complaints: fatigue, paleness, headache, fever, sore throat, upper respiratory tract 
infection and cervical lymphadenopathy. The symptoms disappeared after a week. 
However, two months later, the same symptoms recurred. The GP diagnosed anemia and 
started oral iron substitution therapy. The pediatrician was consulted for the hemolysis. 
    On examination, the pediatrician saw a pale-looking girl, with no other physical signs 
besides lymphadenopathy. Blood tests revealed a hypochromic, macrocytic anemia 
(hemoglobin 5.2 mmol/l) with a positive direct Coombs’ test (anti-IgG: 3+, anti-C3: 2+), 
which is characteristic for an immune-mediated hemolytic anemia. Autoantibody testing 
revealed positive antinuclear and anti-ds-DNA antibodies, combined with low hemolytic 
(CH50 33%, AP50 72%) and immunochemic complement values (C1q 52%, C3 0.39 
g/l and C4 0.03 g/l). Immunofluorescence studies performed on a skin biopsy showed 
granular depositions positive for IgG (++), IgA (+/++), IgM (+++), and C3c (++) along 
the basal membrane, in a few papillae, and to a lesser degree in small subepidermal 
vessels (IgG: +/-, IgA: +/-, IgM: +/++, C3c: +). Viral infections were ruled out. Findings 
matched with an immune complex disease accompanied by a mild vasculitis. The results 
were consistent with autoimmune hemolytic anemia, probably based on an early, yet 
incomplete SLE with, instead of four, three positive criteria of the American College of 
Rheumatology [14]. The family history revealed autoimmune thyroid disease (AITD) in 
four individuals on the maternal side, and systemic lupus erythomatosus (SLE) in the 
deceased aunt on the paternal side, who had also presented with SLE in early childhood.  
    During follow-up at the outpatient clinic, the index patient presented with the same 
symptoms as before. Aggravated hemolysis (hemoglobin 4.8 mmol/l) necessitated 
treatment with prednisone 60 mg daily. After two weeks, the hemoglobin level raised to 
normal. Subsequently, the prednisone dosage was tapered over four months. Ever since, 
the hemolytic complement levels have been normal, while serum C3 and especially C4 
levels have remained subnormal. 
 
 
MATERIALS AND METHODS 
 
Human blood samples. Peripheral blood samples were taken from the SLE patient, her 
father and mother, and the 9 aunts and uncles on the maternal side after informed 
consent had been obtained. 
Complement component C3 and C4 serum levels. These were determined on a BN II 
nephelometer (Dade Behring, Marburg, Germany) according to standard methods. 
Anti-thyroid antibodies. Anti-thyroid peroxidase (TPO) antibodies and anti-
thyroglobulin (TG) were estimated in serum using a BN II nephelometer as well (Dade 
Behring, Marburg, Germany) according to standard methods. 
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Complement component C4 phenotype analysis and the relative quantities of 
C4A and C4B allotypes. Peripheral blood plasma from EDTA samples from the patient 
and her parents was used for C4 allotypic polymorphism testing following standard 
procedures [27]. In short, the plasma was treated with neuraminidase (Sigma, St Louis, 
MO, USA) and carboxypeptidase B (Sigma), and then resolved by high-voltage agarose 
gel electrophoresis (HVAGE) based on gross electric charge differences of plasma 
proteins. C4 was detected by immunofixation with goat anti-human C4 serum (Incstar, 
Stillwater, MN), which was followed by blotting and staining with SimplyBlue Safestain 
(Invitrogen, Carlsbad, CA, USA). The relative intensities of the stain correspond with the 
relative number of C4A and C4B alleles. 
Isolation of genomic DNA and Southern blot analysis. Genomic DNA, to be used for 
restriction fragment length polymorphism (RFLP) analysis, was isolated from peripheral 
blood cells in EDTA samples using the Pure-gene DNA isolation kit from Gentra Systems 
(Minneapolis, MN, USA).  
C4 genotyping and determination of C4A and C4B gene dosage. A two-step 
strategy was employed to determine the number of C4A and C4B genes present in a 
diploid genome (i.e. gene dosage) from each family member. First, primers b, c, and d 
were used for module-specific PCR to decipher the total number of C4 genes [28]. 
Second, primers Y24IN and E29.3 were used for amplification of the C4d region (1.3 
kb in size), which was later subjected to LSP-PshAI RFLP analysis for the elucidation of 
the relative number of C4A and C4B genes [27]. The sequence for primer b was, 5’ 
GCT CAA GCT GTG AGG AGA ACT 3’; c, 5’ TAT CAC AGG CTC TGG CCC CA 
3’; d, 5’ TTC GTG GTC CAG TAC AGG GA 3’; Y24IN, 5' CAG AAG GGT GAG 
TGT CAC CTG AG 3'; and E29.3, 5’ TTG GGT ACT GCG GAA TCC CC 3’. The PCR 
conditions were as follows: 1 cycle at 94ºC for 3 min; 35 cycles at 94ºC for 45 sec, 
62ºC for 45 sec, 72ºC for 1 min; and 1 cycle at 72ºC for 10 min. 20% of the amplified 
products from the module-specific PCR reaction were electrophoresed in 1% agarose 
gels. A digital image of the gel was taken and the intensity of each band was 
quantitatively analyzed by Nucleotech-GelExpert, version 4.0. The amplified products 
from the C4d region were purified and subjected to the LSP method using 0.2 µM [γ-32P] 
ATP-labeled primer E29.3, as described in [28].  LSP products were restriction digested 
with PshAI overnight.  DNA fragments were resolved by electrophoresis using 1.2% 
agarose gels. The gel was subsequently processed by a Southern blot technique, 
subjected to autoradiography, and the radioactivity of each band was registered by 
phosphorimaging and quantified by Molecular Dynamics ImageQuant Software version 
5.0, as described in [28]. Details of the RCCX modules and C4A and C4B gene 
dosages were demonstrated by TaqI RFLP, showing the presence and dosage of RP1-C4 
long (7.0 kb), RP1-C4 short (6.4 kb), RP2-C4 long (6.0 kb) and RP2-C4 short (5.4 kb), 
and by PshAI-PvuII RFLP elucidating the relative dosage of C4A (1.7 kb) and C4B (2.2 
kb). Furthermore, pulsed field gel electrophoresis (PFGE) of PmeI-digested genomic 
DNA was employed to show the RCCX length variants in haplotypes unambiguously 
[28].  
HLA typing. In order to be able to confirm the MHC haplotype situation between the 
patient and her parents, molecular human leukocyte antigen (HLA)-ABC (class I) and 
HLA-DRB1 (class II) typing was performed. In short, leukocytes were isolated from blood 
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drawn from these individuals, and genomic DNA was extracted. Sequence based HLA 
typing was performed according to standard procedures [29]. 
 
 
RESULTS 
 
    Allotyping experiments using blood from the patient and her parents revealed the total 
absence of C4A in the patient’s blood when compared to her parents (Fig. 1).    Plasma 
originating from the parents clearly stained for C4A3, whilst their daughter’s plasma 
showed total absence of C4A3. In plasma of both parents vivid C4B1 staining was 
found. The relative intensity of the C4B1 stain in the paternal plasma already shows the 
presence of more C4B alleles when compared to the maternal plasma or that of the 
patient (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Plasma samples from the positive control (C), father (I), mother (II) and the patient (III) were 
subjected to agarose gel electrophoresis and immunofixation with antiserum to C4 (C4 allotyping), 
showing deficiency of C4A in the patient. Note the strong staining of C4B1 in the father’s serum that, 
after genotyping, could be ascribed to the presence of six C4B alleles. 
 
 
    A pedigree of this family is shown in Fig 2. Serum C4 levels and the number of C4A 
and C4B genes present in the diploid genome of the patient and each family member 
(i.e. gene dosage) are shown in Table 1.In short, the patient (13) has homozygous C4A 
deficiency while the C4B gene dosage is normal with 2 copies of the C4B gene in the 
diploid genome (monomodular RCCX (M): one C4 gene per chromosome). On the 
contrary, the patient’s sister (12) has 5 C4 genes, comprising two C4A genes and three 
C4B genes divided between one bimodular RCCX (B: each copy of chromosome 6 with 
two C4 genes) and one trimodular RCCX (T: each copy of chromosome 6 with three C4 
genes). The patient’s mother (8) has 3 C4 genes in one monomodular and one bimodular 
RCCX (B/M). From the family segregation analysis, it may be inferred that the patient’s 
father (1) has one trimodular RCCX, which was transmitted to the patient’s sister (12), 
and one monomodular RCCX, which was transmitted to the patient (black circle). 
 
C4B1 
 
 
 
C4A3 
     C          I          II       III 
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Figure 2. A genealogical tree showing the homozygous C4A-deficient girl with incomplete SLE (black), 
her non-C4A-deficient sister (12), her parents and family members on the maternal side with 
heterozygous C4A deficiency (1-11). The subjects 2, 3, 4, and 7 suffer from autoimmune thyroid 
disease (AITD). 
 
   However, the results of homozygous bimodular RCCX haplotypes and those of 
trimodular/monomodular haplotypes are indistinguishable by module-specific PCR. 
Therefore, PmeI-PFGE and TaqI RFLP analyses were employed to definitively 
demonstrate the presence of trimodular-LSS (Long-Short-Short) and monomodular-S 
(Short) RCCX structures in the patient’s father (Fig. 3).   
 
 
 
Figure 3. An example of RCCX determination in blood samples from patient’s father (F). A trimodular 
RCCX structure with one long and two short C4 genes on one haploid genome and a monomodular 
RCCX with a single short C4 gene on the other haploid genome (C4A-C4B-C4B / C4B). 
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Table 1. The index patient (no 13) and her family members: serum C4 levels, total C4 gene dosage, 
number of C4A and C4B genes, RCCX modules, antithyroid antibody status, and autoimmune diseases 
as currently diagnosed in this family are included in this table.  
 
No Sex 
Age 
(years) 
Total 
C4 
gene # 
C4A
# 
C4B# Module * Serum 
C4 
(g/l) 
Anti-TG 
(IU/ml) 
Anti-
TPO 
(IU/ml) 
Autoimmune 
disease 
0 F died n.a.    n.a. n.a. n.a.  SLE 
1 M 47 4 1 3 M / T 0.28 < 172 < 20  
2 F 54 3 1 2 M / B 0.22 < 172 139 AITD 
3 F 52 3 1 2 M / B  0.21 < 172 121 AITD 
4 F 51 3 1 2 M / B 0.23 < 172 340 AITD  
5 F 49 3 1 2 M / B 0.18 < 172 < 20  
6 F 49 3 1 2 M / B 0.19 < 172 < 20  
7 M 48 3 1 2 M / B 0.23 < 172 < 20 AITD 
8 F 46 3 1 2 M / B 0.13 < 172 173  
9 F 45 3 1 2 M / B 0.12 1119 624  
10 M 43 3 1 2 M / B 0.19 < 172 < 20  
11 F 40 3 1 2 M / B 0.16 < 172 57  
12 F 16 5 2 3 B / T 0.21 904 < 20  
13 F 13 2 0 2 M / M 0.03   SLE / AIHA 
 
*M: monomodular RCCX, each copy of chromosome 6 contains one C4 gene; B: bimodular RCCX, 
each copy of chromosome 6 has two C4 genes; T: trimodular RCCX; each copy of chromosome 6 has 
three C4 genes. Complement factor C4 levels were measured by nephelometry. Anti-TG: 
antithyroglobulin antibodies. Anti-TPO: antithyroid peroxidase antibodies. AIHA: auto-immune 
hemolytic anemia. AITD: auto-immune thyroid disease. SLE: systemic lupus erythematosus. N.a.: not 
available. 
 
 
    HLA typing of class I and class II alleles (HLA-A, B, C and HLA-DRB1, respectively) 
in the patient and her parents further revealed that the paternal monomodular-S RCCX 
structure of the patient belonged to the HLA-A1 B8 DRB1*11 haplotype, whereas the 
maternal monomodular-S RCCX structure belonged to the HLA-A1 B8 DRB1*03 
haplotype (Fig. 4). 
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Figure 4. HLA typing of the patient and her parents. 
 
 
 
    Anti-thyroid peroxidase antibodies (anti-TPO) and anti-thyroglobulin antibodies (anti-
TG) were measured in sera of all family members. The results are shown in Table 1. 
Clinical thyroid autoimmunity was present in four family members (subjects 2, 3, 4, and 
7). Three of the four family members with thyroid autoimmunity showed increased anti-
TPO. All four individuals suffering from clinical thyroid disease were heterozygous C4A 
deficient. 
 
 
DISCUSSION  
 
    Although the increased prevalence of autoimmune thyroid diseases (AITD) in systemic 
lupus erythematosus (SLE) patients and their families has been reported by several 
researchers over the years, with a reported prevalence of AITD in SLE up to 27%, the 
supposedly combined genetic factor(s) leading to these immune complex diseases still 
remain to be elucidated [15,16]. SLE patients have a 5.7 times higher chance of 
developing thyroid autoimmunity [16]; other researchers have found a marked, though 
age-dependent increase in both thyroid disease and antithyroid antibodies in SLE 
patients themselves [17]. In the case of SLE, C4A*Q0 alleles are part of the 
multifactorial etiology also including other components of the lectin and classical 
pathways of complement activation, Fc receptor polymorphisms, lymphokines, apoptotic 
factors, and HLA-DR2 and -DR3, the serological definitions currently termed DRB1*15 
or DRB1*16, and DRB1*03, respectively [8,18]. In thyroid autoimmunity, the only 
genetic factors known to have a role in etiology are HLA-DR3 (or DRB1*03) molecules 
and the CTLA-4 gene [19]. Although the mother of the SLE patient was DRB1*03 
positive, the father was not, even though SLE was prevalent in his family. For this reason 
we did not pursue this line of genetic research. As an indication of necessity for more 
research, genome-wide screening of SLE patients has been proposed to unravel more 
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factors involved in the pathogenesis of systemic and thyroid autoimmunity [15]. Since the 
prevalence of autoantibodies is known to be raised in relatives of multicase SLE families 
like the family described above, the primary goal of this study was to compare data with 
genetic aberrations of the C4 gene and to test thyroid autoantibody levels in this 
multicase SLE family. 
    The extremely low serum levels of complement component C4 in the above described 
13-year old patient pointed in the direction of C4A deficiency, since the main function 
of the C4A isotype is the mediation of immune complex clearance from the bloodstream 
whereas the C4B isotype is hemolytic and bactericidal. These differences may be 
explained by the fast binding of C4B to hydroxyl groups and the slower binding of C4A 
to amine groups [20]. Only deficiency of C4A, but not of C4B, predisposes to systemic 
autoimmunity. Analysis of deficiencies of the early complement components showed 
that, after allotyping and genetic experiments, this patient’s partial SLE was based on an 
incidental homozygous C4A deficiency combined with a normal C4B gene dosage. 
    Identification of C4A and C4B allotypes are allowed by gross differences in electric 
charges of the variants, resulting in different electrophoretic migration patterns. In plasma 
from the patient’s parents the C4 haplotype A3B1 was found, which is the most frequent 
haplotype among Caucasians (frequency: 0.466) [12]. Over 19 C4A and 22 C4B 
allotypes are recognized besides the null alleles C4A*Q0 and C4B*Q0.  
   C4A and C4B are encoded by genes located in the class III region of the major 
histocompatibility complex (MHC) on chromosome 6. The central MHC is a tightly 
packed and partially overlapping set of genes on chromosome 6, not only encoding 
complement factor C4, but also in the ancient complement proteins C2 and factor B 
[20]. The C4 gene is a constituent of the genetic module termed RCCX, coding not only 
for C4, but also for steroid 21-hydroxylase CYP21, nuclear Ser/Thr protein kinase RP, 
and the extracellular matrix protein tenascin TNX [9]. In a single C4 haplotype, single 
loci exist for RP, CYP21 and TNX, but up to four C4 genes may be found in a haploid 
genome, and each C4 locus may encode C4A and/or C4B [9,21]. The total C4 level in 
serum is determined both by the relative number of C4A and C4B genes present in the 
genome and by the presence or absence of disease leading to C4 consumption in vivo 
[9]. 
    In the index patient, Southern blot analysis was suggestive for complete C4A 
deficiency (absence of C4A protein). Subsequently, using newly established PCR 
genotyping techniques applied to plasma of all family members, the total number of C4 
genes, RCCX modules present on chromosome 6, and the ratio between C4A and C4B 
were determined in blood samples from the patient, her sister and parents, and from nine 
sisters and brothers of the mother. Both parents, and the nine family members from the 
maternal side, had only one C4A gene in the diploid genome. As an example, only 55% 
of Caucasians have the two-locus structure with C4A-C4B configurations in the MHC, 
the remainder has unequal numbers of those genes [8]. 
    Partial C4A or C4B deficiencies in the Caucasian population have a combined 
frequency of 31.6% [8], confirming earlier findings that non-expression of 1, 2, or 3 C4 
alleles is found in 35%, 9% and 1%, respectively [3]. We could show that our young SLE 
patient inherited the HLA-A1 B8 DR3 haplotype with a single C4B gene from her 
mother, and the HLA- A1 B8 DR11 with one C4B gene from her father. 
 88
    Autoimmune thyroid disease (AITD) was diagnosed in one brother and three sisters of 
the patient’s mother. Heterozygous C4A-deficiency was found in these individuals, 
indicating a possible genetic link between SLE and AITD based on C4A deficiency. 
Serum antibodies against thyroid peroxidase, the enzyme that iodinates thyroglobulin, 
are associated significantly with early stages of AITD [22], and have been associated 
with C4AQ0 (null alleles) in literature [23]. Anti-thyroglobulin antibodies seem to 
appear later in thyroid disease and are usually found in sera from patients with 
Hashimoto’s disease.  
    Although thyroid cells are relatively resistant to complement attack, expression of 
CD59 is upregulated in AITD. However, how all other molecules and proteins 
upregulated in AITD and the complement system interact and connect is not entirely 
clear [18]. Why only thyroid cells from individuals suffering from AITD express MHC 
class II molecules, in particular HLA-DR, is unknown. 
    Plasma C4 is synthesized mainly in the liver, although local C4 production may be 
found in organs like the kidneys, heart, synovium, as well as in the skin. Significant levels 
of C4 are synthesized in endocrine organs like adrenals and the thyroid gland [24]. 
Whether deficiency in thyroid C4 production plays a role in AITD is unknown. How then 
may partial C4A deficiency result in thyroid autoimmune disease? It is very likely that 
decreased local C4 production in the thyroid leads to lessened local immunoclearance 
of, for example, thyrogastric autoantobodies, which have been associated with a null 
allele at the C4A locus [23]. Another line of thought may be followed when realizing 
that in totally C4A-deficient patients the organs affected are those that normally 
synthesize C4. 
    As C4 is necessary for the opsonization of immune complexes, allowing ‘immune 
adherence’ of immune complexes (ICs) to C3b-receptors (CR1, CD35) on erythrocytes, 
thus ensuring IC transport to the organs of elimination [25,26] one may speculate on the 
pathological consequences of reduced immune complex clearance in both organ-
specific and non-organ-specific disease. C4 is also involved in chemotaxis of 
inflammatory cells and phagocytosis of ICs, apoptotic particles and, probably, DNA. 
However, it must be kept in mind that the effect of a single genetic factor must be 
interpreted within the shared genetic background in families. Clearly, more studies are 
needed to elucidate other mechanisms involved. 
    In summary, we have demonstrated early onset (partial) SLE in a complete C4A-
deficient Caucasian child, and thyroid autoimmunity in several heterozygous C4A-
deficient family members. More studies in multicase SLE families may uncover the genetic 
etiologies involved in organ-specific and non-organ-specific autoimmune disease. 
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The Ancient Complement System: Role in Microbial Clearance,  
Lipid Transport and Prevention of Autoimmunity 
 
 
    This study concentrates on the complement system, which is part of the nonspecific or 
‘innate’ immune system. The complement system may be considered a primordial enzyme 
system that was, before enhancing cytolysis or ‘killing’, primarily involved in the 
enhancement of cellular transportation of ‘opsonized’ or C3b-laden particles through the 
circulation towards eliminatory organs in the human body.  
 
    In humans and other primates, the adherence of these opsonized particles to the C3b-
receptor (CR1) on cells is called ‘immune adherence’. Although erythrocytes do not 
carry the largest number of CR1s on their surface, their receptors are clustered in such a 
way that erythrocyte ‘immune adherence’ is more efficient than on e.g. neutrophils. 
Moreover, about 95% of CR1s in the circulation are found on erythrocytes, making the 
role of erythrocytes in transport and elimination of microbes, immune complexes and 
tumor cells indispensable. 
 
    Opsonization of immune complexes and transport thereof to the spleen and liver is a 
well-recognized function of the human complement system, as is microbial opsonization. 
Thus, immune complex precipitation disease in vessels (e.g. SLE) and organs (e.g. thyroid 
autoimmunity) is prevented. Microbial opsonization facilitates their adherence to 
erythrocytes and, subsequently, microbial transport to one of the fixed organs of 
phagocytosis where intracellular killing of most of the microbes can take place. However, 
certain (myco)bacteria and parasites have adapted and evolved in such a way that 
intracellular survival and even replication is ensured. 
 
    Our studies concerned the investigation of the prevalence of  MBL deficiency in the 
Dutch population (chapter 3), and the development of a hemolytic MBL assay, which 
may be of great value for the further analysis of MBL and/or MBL-associated protein 
deficiency (chapter 4). By adapting the functional MBL assay, microorganism-induced 
MBL activation could be investigated, leading to a new way of looking at MBL-
activating potencies of microbes, including their filterable products, e.g. presumably 
‘blebs’ which are products of meningococci (chapter 5). Furthermore, Legionella 
pneumophila was found capable of activating the MBL pathway, although this bacterium 
proved to be a weak in-vitro MBL activator. However, this raised the question as to what 
the role of MBL in legionellosis might be. In 1999 in the Netherlands, an outbreak of 
legionellosis occurred at the well-attended Flower Show in Bovenkarspel. By comparing 
the MBL status of sera from that patient cohort versus age-matched controls from the 
Dutch population, we could conclude that MBL deficiency is a risk factor for pneumonia 
with Legionella pneumophila. The prevalence of MBL deficiency (< 0.20 µg per ml) in a 
group of asymptomatic, but exposed workers was similar to the controls (Chapter 6). 
 
    Complement factor C4 is shared by both the lectin and classical complement 
pathways. Like all complement proteins, it is synthesized mainly in the liver. However, the 
thyroid and the adrenals – being endocrine organs – also produce complement C4 
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transcripts but, as yet, the reason for these organs to synthesize C4 is unknown. Possibly, 
the link between (auto)immunity and the endocrine system can be sought at the level of 
the diseased organ, as has been described in chapter 8. The great genetic diversity of 
human C4A and C4B genes leads to both quantitative and qualitative variations of the 
polymorphic C4A and C4B proteins, possibly as an evolutionary answer to selection 
pressure against a great many microorganisms. 
 
    In this thesis, the possibility is considered that other targets of opsonization by the 
complement system are, or can be:  
 
(a)  Lipoproteins, of which at least apolipoprotein B is covered with the MBL-binding 
carbohydrates mannose, N-acetylglucosamine and fucose, which activate the 
complement system via the lectin pathway, as is shown in chapter 7. Normally, after an 
abundant meal, fat is absorbed though the small intestine, where exogenous lipids are 
taken up and incorporated into lipoproteins. These are secreted as chylomicrons into the 
lymph. After entering the systemic circulation, a modulation takes place, mainly 
involving triglyceride hydrolysis by the enzyme lipoprotein lipase (LPL). The remaining 
particles are called ‘remnants’. In the normal situation, most of these pro-atherogenic 
particles are transported to the liver where they are cleared from the circulation by a 
receptor-mediated mechanism. How the transport to the liver takes place is, at present,  
not fully understood. Lipoproteins activate MBL, which is supposedly followed by lipid 
particle opsonization and subsequent adherence of lipoproteins, chylomicrons, or 
remnants to erythrocytes to be, presumably, transported to and cleared by the liver. 
Although more proof is certainly needed, ex-vivo erythrocytes do carry more fat 
particles on their surface after lipid intake as compared to fasting erythrocytes. 
Moreover, MBL deficiency leads to severe atherosclerosis. It seems that the lectin 
pathway is necessary for clearance of lipids, although proving this hypothesis will need 
various longstanding experiments.  
 
(b)  DNA, which is known to activate an as yet unknown complement pathway and 
which, hypothetically, may have been the target of the primitive immune system via MBL 
binding to pentose sugars; these experiments still need to be done. 
 
    By now, it is clear that the lectin and alternative pathways of complement activation 
are the most ancient ones when compared to the classical and terminal complement 
pathways. Possibly, the two pathways constitute two intimately linked parts of a single 
activation pathway in the primitive, jawless deuterosomes, whereas the antibody-
dependent, so-called ‘classical’ pathway of complement activation must have evolved 
about 450 million years ago, when antibodies developed. Thinking in evolutionary 
terms, one may consider that the ancient complement system - as it was - expanded its 
original function in response to microbes, simply because infectious diseases are a heavily 
selective principle that may kill animals (including humans) before sexual maturity. This is 
why the original function of the ancient complement system may have been maintained, 
while the complement system itself drifted away towards a defense mechanism and 
evolved by the inclusion of foreign components and by gene duplication, e.g. in the 
C3/C4/C5/α2M family. Other evolutionary examples are the MBL-derived C1-complex 
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that has capacity to bind IgM and IgG antibodies, its inhibitor C1-INH (C1 esterase 
inhibitor) that actually deserves the more correct name of MBL-INH, and the perforin-
related terminal complement pathway consisting of the components C5b, C6, C7, C8, 
and C9. MBL was a target for the newly evolved IgA. 
 
    According to our hypothesis, the lectin pathway may have initially been created in 
evolution as a mediator of clearance of so-called ‘naked’ DNA and/or as an opsonizing 
step in the clearance of lipid particles from the circulation. Moreover, it was also kindly 
adapted by the immune system to function as a kind of matrix for evolutionary 
development of the extensive complement system as currently described in the 
immunological textbooks. 
 
      During thousands of years, point mutations have arisen in MBL, possibly under the 
influence of radioactive events and UV light during evolution. These deviations from the 
normal mbl gene and promoter gave rise to lowered MBL serum levels. The mutations 
have been positively selected in over 11% of the northern European population and in 
more than 30% of the African population, the latter most probably under the influence 
of infectious diseases like tuberculosis, leprosy, and visceral leishmaniasis, as examples of 
severe infection with intracellular pathogens for which MBL deficiency may be 
protective.  
 
    MBL seems to provide a selective advantage for infection with certain intracellular 
pathogens like mycobacteria and Leishmania. Our finding that MBL deficiency increases 
susceptibility for disease with Legionella pneumophila, also an intracellular 
microorganism, does not fit that idea. Scanty reports in mice and man suggest that MBL 
modulates inflammation by triggering proinflammatory cytokine release. The 
contradictory results raise new ideas for research, e.g. susceptibility of individuals with 
normal serum MBL levels for the intracellular bacterium Salmonella typhi, and the 
subsequent need for vaccination against typhoid fever in travelers. Moreover, one may 
also argue about vaccination against meningococcal disease in subjects with normal 
serum MBL levels, and speculate on complement studies in the ‘meningitis belt’ in Africa 
that could elucidate a connection between MBL deficiency and the occurrence of 
outbreaks of meningococcal meningitis.  
 
     The positive selection of defective MBL alleles in the population is an important cause 
of MBL deficiency-associated hypertriglyceridemia and subsequent atherosclerosis. A 
similar genetic selection may have occurred with the C4A gene. Homozygous C4A 
deficiency leads to autoimmune diseases like systemic lupus erythematosus (SLE), while 
heterozygous C4A, which is also linked with SLE, is associated with autoimmune 
thyroiditis as well. C4A null alleles (C4A*Q0) have not only been associated with an 
increase in circulating immune complexes, but also with premature peripheral 
atherosclerosis. These data indirectly support our hypothesis of the necessity of early 
complement components that are shared by the lectin and the classical pathway, in the 
elimination of lipid particles from the circulation.  
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    Taken together, our findings and hypotheses may lead to an exciting new line of 
research that can, eventually, lead to the rewriting of immunological and physiological 
textbooks. 
 
    In conclusion, the complement system does not only play an important role in the field 
of immunology and (medical) microbiology but it may very well be, as is shown in this 
thesis, one of the key players in the fields of endocrinology and lipidology. The more we 
understand and are able to prove that physiological systems are entwined, both in nature, 
and in man as part of nature, the bigger the notion will be that joining forces between 
medical doctors in various fields and researchers in biology will exponentially increase 
our knowledge and understanding of this intriguing aspect of the world. 
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NEDERLANDSE SAMENVATTING EN DISCUSSIE 
 
 
    Dit proefschrift heeft als onderwerp het zogenoemde Complement Systeem, een 
uitgebreid en – evolutionair gezien – zeer oud afweersysteem tegen wezensvreemde 
micro-organismen. Het complement systeem bestaat uit meer dan 30 eiwitten, en is in 
staat om heel snel te reageren op ongewenste indringers van buitenaf, dat wil zeggen 
binnen seconden tot dagen. Dit is in tegenstelling tot de afweerstoffen, die pas na één of 
meerdere weken worden gevormd.  
 
    De centrale rol in dit systeem wordt gespeeld door het eiwit C3 dat via meerdere 
activatie routes kan worden aangezwengeld (zie hoofdstuk 1, figuur op blz. 12), waarna 
omzetting van C3 naar C3a en C3b volgt. Het aldus ontstane C3b kan zich hechten aan 
oppervlakten van ongewenste micro-organismen, immuuncomplexen en cellen, een 
proces dat ‘opsonisatie’ wordt genoemd. Opsonisatie is het ‘hapklaar maken’ van deeltjes 
voor verdere verwerking in speciale opruimcellen (‘eetcellen’ of macrofagen) in milt, 
lever en longen. Zo worden met C3b-beladen (‘geopsoniseerde’) microben via de C3b-
receptor gebonden aan rode bloedcellen en zo door de bloedbaan getransporteerd in 
de richting van de lever en milt. In de vaste, fagocyterende cellen van bijvoorbeeld de 
milt vindt intracellulaire afdoding plaats van de meeste soorten microben.  
 
    Het complement systeem kan op drie manieren worden geactiveerd (zie blz. 12). De 
drie complement activatie routes heten:  
• de lectine route, met mannose-bindend lectine (MBL) als hoofdspeler. MBL bindt 
gemakkelijk aan de suikers mannose, N-acetylglucosamine en fucose. Deze suikers 
kunnen voorkomen aan de buitenkant van bacteriën, virussen, parasieten en schimmels. 
Als de binding tot stand is gebracht, dan wordt de lectine route geactiveerd. 
• de alternatieve route, welke wordt aangezwengeld door oppervlakten van microben 
en tumorcellen. 
• de ‘klassieke’ route, die antilichamen nodig heeft om te kunnen worden geactiveerd  
 
    Er bestaat ook een vierde complement route, de zogeheten terminale complement 
route, een effector route waarvan het eindprodukt (‘membrane attack complex’) in staat 
is om te doden door gaatjes te maken in cellen en microben (bijv. de meningokok).  
 
     In hoofdstuk 2 wordt uitgelegd wat de basis heeft gevormd voor dit proefschrift: een 
kleine epidemie van hersenvliesontsteking door groep C meningokokken in 
Nijkerkerveen en een verhoogde risico bij een getroffen familie, waarbij een duidelijk 
verband werd vastgesteld tussen doorgemaakte meningokokkenziekte en zeer lage MBL 
spiegels in het bloed.  
    
    Om vast te kunnen stellen hoe verlaagde MBL spiegels in bloedserum zijn verdeeld 
over de algehele Nederlandse bevolking, is een steekproef verricht bij een groep van 
 98
ruim 400 gezonde Nederlanders in de leeftijd tussen 3 en 85 jaar. Dit onderzoek staat 
beschreven in hoofdstuk 3. Wij vonden in deze onderzoeksgroep een verminderde 
hoeveelheid MBL bij 12.2% van onze onderzoeksgroep, en bijna onmeetbare MBL 
spiegels bij 3.1%. Verlaagde MBL spiegels zijn te wijten aan veranderingen in het mbl 
gen en in de promoter, waarbij er 7 verschillende genetische combinaties bekend zijn die 
tot op zekere hoogte de MBL bloedspiegel bepalen. Omdat MBL een oud eiwit is, zijn er 
waarschijnlijk in de loop van de duizenden jaren puntmutaties ontstaan in het genetisch 
materiaal, mogelijk ten gevolge van radioactiviteit en UV-straling. Deze mutaties zijn 
terug te vinden bij meer dan 11% van de Noord-Europese bevolking, en bij meer dan 
30% van de bevolking van Afrika. Dat in Afrika zo’n hoog percentage afwijkend MBL 
wordt gevonden, is mogelijk te wijten aan de evolutionaire invloed van infectieziekten 
als tuberculose, lepra, en kala azar (viscerale leishmaniasis), ziekten veroorzaakt door 
langzaam groeiende, intracellulaire verwekkers waarbij een tekort aan MBL juist lijkt te 
beschermen.  
 
    De twee functionele testen die in de klinische praktijk worden gebruikt om tekorten in 
het complement systeem op te sporen zijn gericht op de klassieke en alternatieve 
complement activatie routes. Deze testen zijn niet geschikt om een tekort aan MBL te 
detecteren. In hoofdstuk 4 wordt een door ons ontwikkelde functionele MBL test 
beschreven; deze kan van grote betekenis zijn voor de verdere analyse van deficiëntie 
van MBL en/of de hulpeiwitten, de zogeheten MASPs (MBL-associated serine 
proteases). De ingrediënten zijn eenvoudig: testserum, bakkersgist als MBL-activator, 
MBL-deficiënt serum als leverancier van alle complement factoren behalve MBL, en 
rode bloedcellen van kippen die fungeren als willekeurig slachtoffer van het ‘membrane 
attack complex’, waardoor de rode bloedcellen uiteen vallen. De relatieve mate van 
roodkleuring in het testsysteem is dan een maat voor MBL activiteit.  
 
    Door de bakkersgist uit de functionele MBL test te vervangen door (verschillende 
concentraties van) andere micro-organismen, kon worden onderzocht in welke mate de 
onderzochte micro-organismen MBL activatie teweeg brengen, zoals beschreven in 
hoofdstuk 5. Op deze manier kan het belang van de lectine route bij de afweer tegen 
verschillende bacteriën en gisten worden gemeten. Ook concludeerden we dat 
filtreerbare bacteriële producten van meningokokken (mogelijkerwijs stukjes 
buitenmembraan) een grote rol spelen bij complement activatie via MBL. Met behulp 
van de functionele test werd de MBL-activerende eigenschap van Legionella 
pneumophila onderzocht, en alhoewel deze bacterie een zwakke MBL activator bleek, 
werd de nieuwsgierigheid gewekt naar de rol van MBL bij Legionella infectie.  
 
    De onderzoeksvraag “welke rol speelt MBL bij Legionella infectie?” is nader uitgewerkt 
in hoofdstuk 6. In 1999 vond in Bovenkarspel, waar de drukbezochte West-Friese Flora 
werd gehouden, een Legionella epidemie plaats. Door MBL te meten in patiëntensera 
versus controlesera uit de Nederlandse bevolking, konden wij concluderen dat een 
ernstig tekort aan MBL een risicofactor vormt voor longontsteking met Legionella 
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pneumophila. De prevalentie van MBL tekort in een groep asymptomatische, doch 
bewezen besmette werkenden bij de Flora was vergelijkbaar met de controlegroep, die 
qua leeftijd overeen kwam.  
 
    Als men resultaten uit hoofdstuk 2 en 5 combineert met de uitkomsten van hoofdstuk 
6, kan men concluderen dat MBL-deficiënte personen een toegenomen kans hebben op 
infecties met sterke MBL activatoren die ook relatief snel groeien in het laboratorium. Uit 
deze conclusie kunnen ideeën voor verder onderzoek ontspruiten, zoals bijvoorbeeld 
naar vatbaarheid voor tyfus (Salmonella typhi) bij reizigers en de daarmee 
samenhangende noodzaak voor vaccinatie. Als men in dezelfde trant door redeneert, 
dan kunnen er vraagtekens worden gezet bij de meningokokken-vaccinatie voor 
personen met een normale MBL serum spiegel, en kan men speculeren over uitkomsten 
van complement studies in de ‘meningitis belt’ in Afrika.  
 
    In hoofdstuk 7 laten we zien dat lipoproteïnen in staat zijn om MBL te activeren. Het 
is bekend dat apolipoproteïne B, een belangrijk suikerig vet van de chylomicronen, aan 
de buitenkant is bezaaid met mannose, N-acetylglucosamine, en fucose, alle drie sterk 
MBL-bindende suikers. Normaliter wordt, na een overvloedige maaltijd, vet 
geadsorbeerd door de dunne darm, waar de vetten worden opgenomen en ingebouwd in 
lipoproteïnen. Deze worden uitgescheiden als chylomicronen (vetbolletjes) naar de 
lymfe waarna, als de bloedbaan is bereikt, een aanpassing plaatsvindt. Dit betreft vooral 
afbraak via hydrolyse van triglyceriden door het enzym lipoproteïne lipase (LPL). De 
resterende deeltjes worden ‘remnants’ genoemd. Theoretisch gezien zou er ‘opsonisatie’ 
van vetpartikels kunnen plaatsvinden, gevolgd door aanhechting van lipoproteïnen, 
chylomicronen, of ‘remnants’ aan rode bloedcellen om daarna te worden 
getransporteerd naar de lever, waar ze worden onttrokken aan de circulatie via een 
receptor gemedieerd mechanisme. Hoe dit transport plaats vindt is onvoldoende bekend. 
Wat verder bekend is, is dat een tekort aan MBL leidt tot ernstige atherosclerose.  
 
    Opsonisatie van immuuncomplexen is een bekende functie van het complement 
systeem. Na binding aan rode bloedcellen via CR1 volgt transport van deze complexen 
naar de milt en lever, Op deze manier wordt het neerslaan van immuuncomplexen in de 
bloedvaten en organen voorkomen. Als immuuncomplexen wel neerslaan in de 
bloedvaten dan kan dat leiden tot systemische lupus erythematosus (SLE). In  hoofdstuk 
8 worden leden van een familie besproken die aan SLE of schildklier-autoimmuniteit 
lijden. Er is bij deze familie gekeken naar een samenhang tussen C4A deficiëntie en 
klinische ziekte. Zoals bij bijna alle complement eiwitten het geval is, wordt C4 vooral in 
de lever gesynthetiseerd. Hoewel ook de schildklier en bijnieren – ook endocriene 
(hormoonproducerende) organen – complement C4 transcripten produceren is het tot 
nu toe onduidelijk waarom deze organen C4 aanmaken. Het is mogelijk dat er een 
verband tussen (auto)immuniteit en het endocriene systeem gevonden kan worden op 
het niveau van het zieke orgaan zelf. De grote genetische diversiteit in C4A and C4B 
genen leidt tot een grote kwantitatieve en kwalitatieve variatie in C4A en C4B eiwitten, 
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waarschijnlijk een evolutionair antwoord op de selectiedruk veroorzaakt door de 
verscheidenheid aan micro-organismen. 
 
    In dit proefschrift wordt beschreven dat er naast micro-organismen, tumorcellen en 
immuuncomplexen, mogelijkerwijs andersoortige partikels zijn die complement activeren, 
zoals lipoproteïnen en DNA (nucleïnezuur). Hoewel (nog) niet door ons bewezen, is het 
goed theoretisch mogelijk dat DNA via de lectine route het complement systeem 
activeert. Op theoretische gronden mag men aannemen dat via de pentose suikers 
binding van DNA aan MBL zou kunnen plaatsvinden. Zogeheten ‘naakt’ DNA zou het 
eerste doelwit van het primitieve afweersysteem kunnen zijn geweest. Volgens onze 
hypothese is de lectine route vooraleerst ontstaan als een mediator van de klaring van 
DNA en/of als een opsoniserende stap in de klaring van vetdeeltjes uit de bloedbaan. 
Hoe dan ook, het primitieve complement systeem werd een soort matrix voor de 
evolutionaire ontwikkeling van het uitgebreide complement systeem zoals op dit moment 
beschreven.  
 
     Door de uitselectie van afwijkende MBL allelen (een van de genen die op een 
bepaalde plaats in het chromosoom kan voorkomen) in de bevolking zou een belangrijke 
oorzaak kunnen zijn voor de MBL-deficiëntie-geassocieerde hypertriglyceridemie en 
atherosclerose. Een vergelijkbare selectie zou plaatsgevonden kunnen hebben bij het 
C4A gen. Homozygote C4A deficiëntie (het ontbreken van genen op beide 
chromosomen) leidt tot auto-immuunziekten als ‘systemic lupus erythematosus’ (SLE) 
terwijl heterozygote C4A deficiëntie (met ongelijke allelen), welke ook een link heeft 
met SLE, tevens is geassocieerd met auto-immuun schildklierontsteking. Het ontbreken 
van (een deel van) de C4A genen is niet alleen geassocieerd met een toename van 
circulerende immuuncomplexen in de bloedbaan, maar ook met vroegtijdige perifere 
atherosclerose. Deze data ondersteunen op een indirecte manier onze hypothese dat 
complementfactoren uit zowel de lectine als de klassieke route een rol spelen bij de 
eliminatie van vetdeeltjes uit de circulatie.  
 
    Dit alles in overweging nemende, zouden onze bevindingen en hypothesen kunnen 
leiden tot een spannende, nieuwe onderzoekslijn die eventueel zou kunnen leiden tot het 
herschrijven van immunologische en fysiologische boeken.  
 
    Kortom, het complement systeem speelt niet alleen een belangrijke rol in de 
immunologie en (medische) microbiologie maar, zoals dat wordt beschreven in dit 
proefschrift, het zou ook een belangrijke speler kunnen zijn in het veld van de 
endocrinologie en lipidologie. Hoe meer we begrijpen en kunnen bewijzen dat 
fysiologische systemen onderling verbonden zijn, zowel in de natuur als in de mens die 
daarvan deel uitmaakt, hoe groter het besef dat door het samenwerken van artsen in 
verschillende specialismen en onderzoekers in de biologie onze kennis en ons begrip van 
dit boeiende aspect van de wereld exponentieel zal groeien. 
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    De schrijver van dit proefschrift werd op 21 mei 1964 geboren als tweede van een 
tweeling in het toenmalige Diakonessenziekenhuis in Arnhem. Na bezoek aan de 
kleuterschool ‘de Narcis’ liep zij door naar de lagere school ‘De Sterrenberg’. Eind 1971 
vertrok het gehele gezin Kuipers, bestaande uit de ouders met vier dochters, vanuit 
Arnhem naar India, waar zij zich vestigden in de plaats Poona (thans Pune genaamd). Op 
dat moment brak – letterlijk – een oorlog uit. Na een half jaar privé onderwijs mocht het 
leergierige meisje per auto met chauffeur naar de meisjesschool “St. Mary’s”, alwaar 
onder de krachtige leiding van Anglicaanse nonnen werd kennisgemaakt met het Britse 
schoolsysteem, inclusief prijzenstelsel. Eenmaal terug in Nederland doorliep zij VWO-B 
aan het Christelijk Atheneum te Arnhem. Vanaf 1982 studeerde zij Geneeskunde aan 
de Universiteit Utrecht. In 1987 keerde ze terug naar India voor een stage in een 
lepracentrum in Tamil Nadu. In 1989 werden een aantal co-assistentschappen gelopen 
in Suriname en Curaçao, waarna eind 1990 het artsexamen met goed gevolg werd 
afgelegd.    
    In 1991 was zij ruim 100 uur per week werkzaam in Frimley, Surrey, Engeland, als 
assistent Chirurgie bij lever- en pancreasspecialist Mr. I. Paterson. Daarna volgde 
gedurende een jaar een assistentschap op de Intensive Care van ziekenhuis ‘de 
Weezenlanden’ in Zwolle onder leiding van thoraxanesthioloog B. Mooi. In januari 
1993 werd het Amerikaanse artsdiploma behaald (FMGEMS). Om brood mèt kaas te 
kunnen verorberen werd daarna de functie vervuld van Clinical Research Associate bij 
MIRAI in Amsterdam. 
    De loopbaan in de Microbiologie begon in februari 1994 met een AGNIO-schap 
Medische Microbiologie bij het SSDZ (Stichting Samenwerking Delftse Ziekenhuizen) en 
Reinier de Graaf Gasthuis te Delft. Dit was ook de plaats waar zij haar geliefde Joris F. 
van Eekhout ontmoette. Van 1995 tot 1999 was zij in opleiding tot arts-microbioloog in 
het Academisch Ziekenhuis Utrecht bij Prof.dr. J. Verhoef, en in het Diakonessenhuis 
Utrecht bij Dr. R. Diepersloot. Begin 1997 begon zij aan de voorbereiding van dit 
proefschrift onder leiding van Prof.dr. H. van Dijk.  
    Sinds 1 maart 1999 is zij als arts-microbioloog verbonden aan het Laboratorium 
Microbiologie Twente Achterhoek te Enschede. Van daaruit is zij werkzaam als 
consulent klinische microbiologie en infectieziekten, en is tevens staflid van het 
Streekziekenhuis Midden-Twente te Hengelo. 
